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I. INTRODUCTION 
 
1 CARDIOVASCULAR DISEASES – A CONTINOUSLY SPREADING EPIDEMIC 
Pathologies affecting heart and blood vessels such as coronary heart disease, cerebrovascular disease 
or peripheral arterial disease, are grouped under the term cardiovascular diseases (CVDs). They re-
main the major global cause of death representing 30% of the total number of deaths worldwide. Cur-
rently, 17.3 million fatal casualties per year are caused by CVDs, among them 7.3 million due to coro-
nary heart disease and 6.2 million due to stroke.1 These numbers show a strong tendency to enlarge. 
For 2030, the World Health Organization (WHO) is currently projecting a number of 23.3 million 
deaths due to CVDs.1 Therefore, an early case specific medical treatment on the one hand, and preven-
tion on the other hand is and will be vital.  
1.1 Cause of disease 
In most cases, the etiology and the correspondent histopathologic finding in these patients is athero-
sclerosis. It is characterized by intima damage resulting from cholesterol deposits into the arterial wall 
and a subsequent incomplete inflammatory response due to failure of adequate phagocytosis of oxi-
dized cholesterol by macrophages.2 Their degradation to foam cells and the accumulation of cell debris 
does not only further chronic vessel wall damage and inflammation but also the hardening of the ves-
sel. The accumulation of foam cells, called atheromatous plaque, can be instable (i.e. vulnerable), and 
is prone to rupture thus occluding the arterial vessel. The clinical presentation of temporary arterial 
occlusions is, for example, recurrent episodes of chest pain, transient ischemic attacks or intermittent 
claudication in peripheral arterial disease.  
Prevention is the best form of medicine comprising the reduction of risk factors (RFs) leading to ath-
erosclerosis to reduce the incidence of disease. Due to the high morbidity, CVDs have become a seri-
ous burden for every health care system in the western world and are already escalating in newly in-
dustrialized countries. Ironically, the alleged advantages of a modern, comfortable lifestyle promote 
their prevalence. Risk factors are generally classified in modifiable risk factors such as an unhealthy 
diet, physical inactivity, tobacco abuse, hyperlipidemia, hypertension, diabetes or the metabolic syn-
drome and non-modifiable RFs like age, sex or genetic predisposition evidencing that not every risk 
factor for atherosclerosis is in fact controllable.3 However, 80% of coronary heart disease and cerebro-
vascular disease are indeed due to the behavioral risk factors physical inactivity, unhealthy diet and 
tobacco abuse.1 So although promising, preventive medicine has not been successful to efficiently 
reduce the prevalence of those behavioral risk factors and the incidence of atherosclerosis related 
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CVDs in the public. As mentioned before, their prevalence is rather increasing and, accordingly, the 
demand for a fast, accessible and efficient therapy is also continuously growing.  
1.2 New therapeutic strategies 
The survival rate for a life threatening acute vessel occlusion such as myocardial infarction is still low 
with adequate primary care, short transport time (“door-to-balloon time”) to a cardiac center providing 
fast accessible primary percutaneous coronary intervention (PCI) or cardiac bypass surgery being the 
most relevant factors these days for the outcome of patients (“time is muscle”).4 Although an increas-
ing number of hospitals can provide these procedures, still a considerable percentage of patients can-
not be treated this way or the attempted PCI/bypass surgery turns out to be unsuccessful and in 3rd 
world countries, most patients are unable to gain access to these treatments at all. As already stated, 
the patients’ survival is merely a matter of time-to-treatment in the acute event but distinct structural 
preconditions in the vasculature can improve the patients’ outcome significantly. Therefore, aside 
from educating the population to a healthier lifestyle and the ongoing technical advances in emergency 
medicine and PCI techniques, a large field of research is currently exploring new ideas to prevent 
CVDs and/or treat them from a different point of view. The cardiovascular system has an immense 
capacity to dynamically adapt to different conditions and pathologies. The door to new therapeutic 
options lies in the understanding of the dynamics between the molecular processes that promote the 
progression of disease and the compensatory mechanisms that take place in the living organism. In a 
recent study, it was shown that well developed preexistent collateral networks are associated with an 
improved long-term survival of patients after ST-segment elevation myocardial infarction (STEMI).5 
So apart from medical treatment and prevention, distinct anatomical advantages such as an efficient 
preexistent collateral circulation can apparently cope better with the incidence of a major artery occlu-
sion by maintaining sufficient oxygen supply for the muscle.  
1.3 Discovery of a collateral circulation 
The recognition of a preexistent collateral network capable of remodeling preceded a 300-years lasting 
debate. In 1669, the British physician Richard Lower (1631-1691) reported for the first time findings 
of collateral arteries he had found between the right and the left coronary artery by injecting fluid into 
one artery and observing its appearance on the other.6 The Swiss anatomist Albrecht von Haller (1708-
1777) described 1757 functional, interarterially connecting vessels in the apex region and in the sulcus 
longitudinalis of the posterior ventricle.7 In 1785, John Hunter (1728-1793), a Scottish surgeon ap-
pointed to King George III, developed a new and modern technique for the treatment of traumatic 
popliteal aneurysms in patients on the basis of animal experiments using collateral artery growth (see 
Discussion 1.1).8 A 100 years later distinguished anatomists like Hyrtl, Henle and Cohnheim denied 
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the collateral arteries’ existence and proposed these vessels to be “simple” end arteries.9 In the begin-
ning of the 20th century, the works of the anatomist Werner Spalteholz (1862-1940) depicted clearly a 
coronary collateral circulation.10 Up until then, pathologists and anatomists used three methods: direct 
preparation, cast corrosion or radiographs after injection of opaque media, which in those times was 
still in its infancy. Spalteholz developed a new technique to make specimens transparent after injection 
of vessels with opaque media, to allow an excellent view inside the organ in its nearly untouched 
threedimensional structural entity,11 a method that is still used today with marginal changes. Although 
Jamin confirmed his findings using X-ray technique,12 the criticism persisted and it was not until the 
works of Longland13 (1953) and Fulton14 (1965) when the hypothesis of end arteries was finally disap-
proved. Longland demonstrated that collateral arteries consist of a stem, mid-zone and re-entrant.13 
Fulton described collaterals as anastomoses being detectable in health and disease. He also related 
distinct vascular growth patterns to the level of ischemic impairment of the myocardium.14 The rela-
tionship between collateralization and the atherosclerotic burden in coronary vessels moved into the 
center of attention. What did stimulate the development of these networks, why did they develop in 
some patients suffering from atherosclerosis and not in all of them? And more importantly, could the 
vessels’ growth be stimulated?  
2 FORMATION OF BLOOD VESSELS 
Tissue homeostasis and vitality is strongly dependent on the adequate oxygen supply maintained by 
blood within a fine branching vessel network. Blood vessels form not only during the embryonic stag-
es, they adapt in adults in response to changing stimuli, in physiologic and pathologic states. Blood 
vessel formation and remodeling have been investigated by various disciplines, and different forms of 
vascular growth have been identified (Figure 1). 
2.1 Vasculogenesis 
During the early stages of embryonic development, pluripotent hemangioblasts, precursor cells for 
both hematopoetic and endothelial cells, differentiate from mesodermal cells of the splanchnic layer 
located in the lateral plate mesoderm.15 They condense to large cellular aggregates (blood islands).16 In 
the inner layer, hemangioblasts differentiate to hematopoetic stem cells whereas in the outer layer, 
they become angioblasts, which are capable to migrate considerably17 until they differentiate again to 
CD34+/CD133+ endothelial precursor cells (EPCs) and form the lining of primary capillary networks 
(Fig 1A). Growth factors (GF) such as vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF) 2 mediate vasculogenesis. FGF-2 is required for the differentiation of hemangio-
blasts from the splanchnic mesoderm and the formation of the blood islands16 and VEGF and its recep-
tors Flk1 and Flt1 regulate the differentiation of the angioblasts to form endothelial tubes.18, 19 During 
 INTRODUCTION  
 
 4 
the ongoing embryonic development, the initial networks differentiate to mature vessels that are 
pruned to a complex network of communicating arteries and veins mostly via sprouting mechanisms 
(see below). Circulating CD34+/CD133+ cells are detectable in the blood of adults, which led to the 
hypothesis that vasculogenesis might not be restricted to ontogenesis and can be occurring in the adult 
as well.17 Whether EPCs might be used as a therapeutic option in CVDs is discussed controversially 
under current preclinical and clinical investigations.20 
 
Figure 1: Different types of vascular growth (modified from17) 
A: Vasculogenesis: In situ development of primitive capillary networks from endothelial progenitor cells devel-
oped from angioblasts.  
B: Angiogenesis: De novo formation of capillary networks from preexisting postcapillary networks. Schematic 
overview showing the three known mechanisms: sprouting, intussusception and bridging. 
C: Arteriogenesis: Shear stress mediated collateral artery growth, forming vessels that are capable to compensate 
for a stenosis in a major arterial vessel. 
2.2 Angiogenesis 
Angiogenesis defines the formation of capillary networks from preexisting postcapillary microvessels 
and is a pivotal element in processes such as wound healing or inflammation. Initially, the term was 
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introduced 1935 by Hertig to describe the vascular adaptive processes within the placenta during preg-
nancy.21 Today, angiogenesis is mostly investigated to explore pathologic states such as inflammation, 
neoplasia or diabetic retinopathy. Angiogenesis occurs via three major mechanisms: sprouting, intus-
susception and bridging (Fig. 1B). Sprouting terms the extending of sprouts from sides and ends of 
preexisting vessels and is the process that has been mostly studied. Intussusception forms vessels by 
longitudinal division out of the preexisting vessel by pillars of peri-endothelial cells and bridging de-
scribes the development of transendothelial cell bridges, which then separate into individual capillaries 
of 5-8µm in diameter.22 Tissue hypoxia is the initial stimulus that triggers angiogenesis. Activated 
endothelial cells release nitric oxide (NO) mediating immediate vasodilatation. When pO2 levels drop, 
the α-subunit of hypoxia inducible transcription factor -1 (HIF-1α) is stabilized, translocates into the 
nucleus and forms a dimer with the ß-subunit (HIF-1β). This activates the transcription of HIF-1 target 
genes, among them VEGF, a very potent angiogenic GF.23 Apart from transcriptional regulation, aug-
mented VEGF mRNA stability in response to hypoxia promotes the enhanced expression of VEGF.24 
VEGF promotes vasopermeability and subsequently the extravasation of plasma proteins serving as a 
scaffold for migrating endothelial cells (ECs).17 The next step is the degradation of the extracellular 
matrix and the basement membrane by matrix metalloproteinases (MMPs), chymases, heparanases and 
serine proteases.22 The urokinase plasminogen activator (uPA) and tissue PA (tPA) convert the plasma 
protein plasminogen to plasmin, which subsequently activates several MMPs and degrades structural 
proteins such as laminin and fibronectin.25 The exposed endothelial cells proliferate and sprout from 
these regions, directed by chemotactic factors released from fibroblasts, neutrophils, monocytes or 
mast cells. Angiogenesis is orchestrated by VEGF, FGF, and platelet-derived GF (PDGF) promoting 
the growing of the new capillary. Antiangiogenic signals prevent an overshooting and undirected pro-
liferation (see below). NO terminates the proliferative actions of growth factors and promotes the for-
mation of vascular tubes.26 Then, pericytes are recruited along the newly formed structures. Angiopoi-
etin-1 (Ang-1) and its tyrosine receptor kinase Tie-2, stabilize the immature endothelial cell network, 
attract pericytes and maintain biochemical interactions and vessel integrity and may play an important 
role in the organization and maturation of vessels. Transforming growth factor-beta 1 (TGF-ß1) 
strengthens the extracellular matrix and furthers the differentiation and maturation of pericytes.27 Re-
modeling and „pruning” of capillary–like vessels eventually results into a structured network of 
branching capillaries. It’s important to note, however, that within the angiogenic formation vascular 
smooth muscle cells (vSMC) are hardly involved. Capillaries do not hold a vSMC-layer in order to 
maintain vascular tone as conductance arteries do. For clinicians, angiogenesis is an extremely im-
portant mechanism, mostly due to its significance for tumor pathology. Folkmann used the term to 
describe neovascularization during tumor growth and formed the concept that tumor growth could be 
controlled by inhibition of angiogenesis. Neoplasia therefore directly depends on an adequate access to 
the circulatory system in terms of tumor mass enlargement and metastasis.28 Under physiological cir-
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cumstances new vessels mature and become stable. In tumors, vessels do not become quiescent, show 
unusual, irregular architecture and remain often leaky since the vascular growth is not properly guided. 
A critical step towards tumor progression is the angiogenic switch where angiogenesis is initiated in 
the dormant primary tumor nodule to mediate exponential tumor growth and enable metastasis.29 The 
difference between physiologic and tumor angiogenesis is that the usually balanced signaling between 
physiologic proangiogenic (e.g. VEGF, FGF) and antiangiogenic factors (e.g. thrombospondin, angio-
statin) becomes destabilized.30 There is evidence that also EPCs recruited from the bone marrow par-
ticipate in the angiogenic switch.31 The discovery of potential targets for an anti-angiogenic tumor 
therapy targeting especially the initiation of the switch led to the development of antiangiogenic drugs. 
The appropriate and safe application in terms of a prolonged survival of patients whithout severe side 
effects is already tested in clinical settings for example for anti-VEGF-A (Bevacizumab [Avastin] ) 
and anti-VEGF-receptor (Cediranib [Recentin]) drugs. Cediranib failed in clinical trials due to ineffi-
ciency combined with deleterious side effects32 whereas Bevacizumab was approved by the U.S. Food 
and Drug Administration (FDA) for metastatic colorectal carcinoma and glioblastoma multiforme, 
among others.33 However, due to severe side effects and high therapy costs this therapy regime does 
not belong to the standard. So it seems that further investigations are necessary since the inhibition of 
overall angiogenesis interferes greatly with the physiologic angiogenesis processes and is thus seldom 
tolerated.  
2.3 Arteriogenesis 
Arteriogenesis is defined as the process of collateral artery growth, meaning the transformation of 
preexistent collateral arteries in order to compensate a stenosis of a major arterial vessel. It is a life 
saving process, not only in the case of myocardial infarction.5 Coarctation of the aorta is a congenital 
disease where the aorta is constricted around the area of the ligamentum arteriosum. In the case of the 
postductal coarctation, patients develop an impressive collateral artery network via the intercostal ar-
teries leading to notching of the ribs. Without the body’s impressive capability to develop these arter-
ies the narrowing of the human body’s largest artery would hardly be survivable. Typically, hemody-
namic forces such as fluid shear stress (FSS) and circumferential wall stress not ischemia trigger and 
promote collateral artery growth.34 Crucial mechanism involve leukocyte, especially monocyte re-
cruitment and proliferation of ECs and vSMCs (see below). The mature, natural bypasses show an 
increase in diameter and length and therefore develop a typical corkscrew-like morphology. The work-
ing group around Wolfgang Schaper rendered important services to the identification of mechanisms 
regulating collateral artery growth and its differences to angiogenesis. In 1971 they demonstrated for 
the first time that preexistent arteriolar anastomoses enlarged due to proliferation of vascular cells and 
not by mere vasodilatation.35 Whereas the diameter can increase up to 20-times,36 the capability of 
remodeling within these vessels is limited to 35 to 40 percent of the origin conductance.34 Pre-existing 
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collateral arterioles usually show an internal diameter between 30 and 50µm37 and are microvascular, 
thin-walled conduits comprising an endothelial layer, an internal elastic lamina and one or two layers 
of SMCs.13 The number and capability of remodeling of these interconnecting vessels varies among 
species and within individuals36 and becomes impaired during aging.38 During the remodeling process, 
the collateral system prefers few large conduct collaterals instead, resulting in the regression of many 
small ones, a process called “pruning”.37 
3 MECHANISMS PROMOTING ARTERIOGENESIS 
In the past 15 years research has been conducted extensively in the field of arteriogenesis to identify 
important mechanisms, mediators and signals with the future goal to offer patients the therapeutic 
alternative of iatrogenic accelerated collateral artery growth.  
3.1 Hemodynamic forces 
Blood flow through arterial vascular networks is a biomechanical stressor. Different physical parame-
ters influence the homeostasis in the arterial wall: blood pressure, hydrostatic pressure, circumferential 
wall stress (CWS) and FSS. CWS, endured by the smooth muscle, is directly proportional to the intra-
vascular pressure and inversely proportional to wall thickness and is a 106 times stronger force than 
FSS.39 After an acute occlusion or severe stenosis of a major artery, a steep pressure gradient between 
the high-pressure pre-occlusive area and the low-pressure post-occlusive region develops. Blood flow 
is now redirected along this pressure gradient, thereby recruiting the preexisting collateral network. 
Shear rate is a gradient of velocity; an increase in the axial blood flow velocity from the vessel wall 
towards the center of the lumen is defined as simple shear rate in s-1. For a simplified understanding of 
shear, the rheology of Newtonian fluids (i.e. water) with laminar flow and constant viscosity can be 
contemplated in this model. For the purpose to describe the basic mechanisms that occur within the 
collateral vessel, these equations shall be sufficient.  
 
A Newtonian fluid’s shear rate !γ  at the inner wall of a pipe is defined as: 
 !γ = 8νd   (1) 
Where: !γ = shear rate in s-1, ν = linear fluid velocity, d = diameter (= 2 ∗ the radius r) of the pipe. 
Along with ν =
Q
A  (Q being the volume flow rate 
dV
dt in m
3/s) and A = πr2 (A being the area cross-
section), the formula can be formed to: 
 !γ =
8 Q
πr2
!
"
#
$
%
&
2r =
4Q
πr3  (2) 
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As seen in the equations, shear rate is directly proportional to blood flow velocity (1) and inversely 
related to the third power of the vessel radius (2). Therefore, an increase in blood flow within the col-
lateral network with small vessel diameters ranging from 50µ- 100µm leads to an increase in shear 
along the collateral endothelium.  
 
For Newtonian fluids, wall shear stress (τ w ) in Pa (former unit used dyn/cm
2) can be related to the 
shear rate reliant on dynamic viscosity (µ ):  τ w = !γ
∗µ    
 
Although the rheology of non-Newtonian fluids (i.e. blood) where pressure, velocity and the fluid’s 
viscosity varies periodically would be more accurate, biological fluid modeling is far from being trivi-
al.40 More accurate models to describe blood flow and shear within tortuous arterioles are currently in 
the process of development.41 The average blood flow in a normal, healthy femoral artery results in 
shear stress values of 4.8*10-3dyn/cm2. After femoral artery occlusion, the FSS within the collaterals 
increases by nearly 200-fold to 889*10-3dyn/cm2, an intense stimulus.9 The German anatomist Thoma 
described in his “Law of Histomechanics”42 the relationship between the size of an artery and the 
blood flow velocity within. Large vessels with a low flow tend to reduce their lumen, whereas small 
vessels with a high flow tend to widen it (like collateral vessels).42 In the works of Langille,38 Holtz,43 
and Ben Driss44 it was also shown that changes in arterial blood flow lead to the immediate adjustment 
of vascular tone and subsequently also a structural reorganisation of the vessel wall in response to a 
persisting change of blood flow. A sustained increase in fluid shear stress is the stimulus for the acti-
vation of the endothelium characterized by swelling and edema and the start for the remodeling pro-
cess.39 With the increase in diameter, however, the FSS decreases together with the stimulus to grow. 
In an experimental setting it was shown that under artificially sustained high FSS within collateral 
arteries of the hind limb via a generated shunt, a 4-fold increase of collateral flow compared with the 
contra-lateral ligated, but not shunted hind limb could be obtained.45 FSS does therefore not only trig-
ger arteriogenesis it also maintains the ongoing process. The stimulus is then “translated” into gene 
activation and expression. This process of mechanotransduction is not entirely understood. ECs detect 
alterations in FSS and respond with a variety of mechanisms ranging from electrophysical modulation 
of membrane proteins (second messengers) or ion channels46 to cellular reorganization of the cytoskel-
eton,47 to activation of a number of genes like platelet endothelial cell adhesion molecule 1 (PECAM-
1),48 endothelial NO synthase (eNOS), or intercellular adhesion molecule -1 (ICAM-1).49 Signal trans-
duction cascades are then activated and transmit the stimulus from surface into the nucleus such as the 
mitogen-activated protein kinase kinase (MEK) /extracellular signal-related kinase 1/2 (ERK1/2) 
pathway50 mediating the subsequent steps towards mature collaterals. 
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3.2 Monocyte recruitment 
The activated endothelium expresses a number of cell adhesion molecules and releases cytokines at-
tracting circulating blood cells.51 Arteriogenesis strongly depends rather on the recruitment of blood 
monocytes52 than on granulocytes or T-cells.53 However, only 4-8% of all leukocytes comprise mono-
cytes. In response to invasive stimuli and inflammation, their percentage can increase dramatically. 
Circulating monocytes possess migratory, chemotactic and phagocytotic activities. The attraction of 
monocytes to the vascular wall is characterized by tethering, rolling and finally the firm adherence at 
the endothelium.52 They migrate through the vessel wall (diapedesis), accumulate around the growing 
arterial vessel and differentiate into tissue macrophages. Their accumulation starts around 12h and 
cumulates on day 2-3 after the induction of arteriogenesis by femoral artery occlusion.51 The attach-
ment of monocytes to the collateral endothelium was observed for the first time in the canine heart.54 
Studies using electron microscopy delivered some evidence for a direct transmigration through the 
arteriolar wall. It is however not entirely proven whether monocytes transmigrate only through the 
collateral artery or perhaps also through the adjacent venules as the vessels’ close proximity suggest 
(Figure 2). Nevertheless, the presence of monocytes and macrophages has been shown to be important 
for the development of collateral arteries, since they themselves are the providers of numerous cyto-
kines (e.g. MCP-1), growth factors (e.g. FGFs) and MMPs.55, 56 Various signaling molecules and cyto-
kines trigger and maintain the transmigration of monocytes. 
 
Figure 2: Close proximity of venules and arterioles in the collateral circulation. 
Photography shows collateral arteriole (upper vessel) and venule (lower vessel) branching from/to the vasa 
femoralia in the murine hindlimb. 
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3.2.1 Monocyte chemoattractant protein 1 (MCP-1) 
Chemokines are a heterogenic group of small chemotactic cytokines (8-10kDa) responsible for attrac-
tion, migration and activation of leukocytes. They exert their biological function by binding to specific 
G-protein-linked transmembrane receptors and are divided into four major families according to the 
spacing of their first two cysteine (C) residues. CC-chemokines contain two cysteine residues adjacent 
to each other and are responsible for attracting mononuclear cells to sites of inflammation. The other 
families comprise the CXC-chemokines (C residues separated by one aminoacid) e.g. IL-8, the C-
chemokines (with only 2 cysteines), and the CX3C- chemokine (three aminoacids between the Cyste-
ine residues) with the only member fractalkine.57 The best-studied chemokines of the CC group are the 
monocyte chemoattractant proteins (MCPs) 1-5. MCP-1, also known as CCL2 (CC-ligand 2),58 is a 
potent chemoattractant for monocytes, T lymphocytes and basophils.57 Other members of the CC-
chemokine family include macrophage inflammatory proteins (MIPs) α, β, γ and RANTES (Regulated 
upon Activation, Normal T-cell Expressed, and Secreted also known as CCL5). The expression of 
MCP-1 is regulated by growth factors (e.g. VEGF and FGF-2) but also in response to FSS. MCP-1 
acts proarteriogenic during arteriogenesis recruiting monocytes to the site of collateral artery growth 
thereby promoting the remodeling of the vessels.59 Constant local administration of MCP-1 into the 
proximal stump of the occluded artery via an osmotic minipump resulted in an increase of collateral 
conductance in the thigh area of the rabbit.60  
3.2.2 Intercellular adhesion molecule 1 (ICAM-1) 
Activated endothelial cells express both intercellular and vascular cell adhesion molecules (ICAM-1 
and VCAM-1). They belong to the immunoglobulin superfamily and are cell surface glycopeptides. 
Their mRNA has been found upregulated at 12h (VCAM-1 and ICAM-1) and 24h (only ICAM-1) 
during arteriogenesis in the rabbit hindlimb.51 ICAM-1 is a ligand for the integrins lymphocyte func-
tion-associated antigen 1 (LFA-1) and macrophage-1 antigen (Mac-1) on monocytes and fibrinogen 
and is therefore an important mediator of leukocyte transmigration during arteriogenesis.60 Integrins 
are heterodimeric cell surface receptors composed of two trans-membrane glycoproteins: a variable α-
chain and a non-variable β-chain; LFA-1 and Mac-1 belong to the β2-subfamily. Integrins mediate 
attachment of cells to the matrix, cell-to-cell connections, and regulate intracellular signal transduc-
tion.61 Monocytes bind to the ICAM-1 molecules on endothelial cells by their Mac-1 receptor, invade 
the vascular wall and accumulate in clusters in the adventitia and the perivascular space of the growing 
artery. Monocyte attachment and arteriogenesis was shown to be impaired after intravenous infusion 
of anti-ICAM-1 antibodies.62  
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3.2.3 Urokinase-type plasminogen activator (uPA) 
During the recruitment of cells into the perivascular space the extracellular matrix (ECM) has to be 
degraded to provide space first for the migrating cells, next for the remodeling vessel. ECs, vSMCs 
and macrophages release matrix-degrading proteinases. The balance between proteolysis and stabiliza-
tion of the ECM is shifted and the two systems of MMPs and uPA are activated.63 MMP-2 and MMP-
9 have been found upregulated in arteriogenesis.63 uPA is a serine protease with the substrate plasmin-
ogen. By activating plasmin, it triggers proteolysis cascades that, depending on the environment, may 
lead to thrombolysis or degradation of the extracellular matrix. Monocyte migration in vitro critically 
depends on uPA.64 Moreover, uPA derived from monocytes can mediate vSMC migration.65 In vivo, 
the the transmigration of neutrophils66 as well as the accumulation of monocytes in the perivascular 
space of growing collaterals67 also depends on uPA but not on the interaction with its receptor uPAR.  
3.3 Vascular cell proliferation and differentiation 
Arteriogenesis does critically depend on the proliferation of endothelial and smooth muscle cells.34, 35 
The proliferation phase in the rabbit hind limb begins 24h after arterial occlusion in the mid zone and 
peaks at day three to seven.51 During this phase, an increased mitotic and proliferative activity of en-
dothelial cells, smooth muscle cells and fibroblasts can be observed. This time window coincides with 
the presence of monocytes in the perivascular space. vSMCs demonstrate the most critical change 
during the maturation of the vessel. First, they increase their tissue mass 3-fold in mice, 10-fold in 
rabbits 20-fold in canines and more in humans.68 This is mainly due to the phenotype switch from the 
contractile to the synthetic type that occurs in vSMCs and which depends critically on the downregula-
tion of the transcriptional repressor splicing factor -1 (SF-1)69 and of the cytoskeletal protein αSM-
actin.70, 71 The lamina elastica interna of the arterial vessel is digested by elastases and is later detecta-
ble in form of fragments. Migrating vSMCs loose their contractile apparatus, showing reduced 
amounts of the cytoskeleton protein alpha-smooth muscle actin (αSM-actin) but abundant amounts of 
depolymerized actin and depict a prominent rough endoplasmatic reticulum especially around day five 
to seven.51 Now accumulated in the intima, they enter the cell cycle and divide. But mitosis also oc-
curs within the media.35 The filament protein desmin, a marker for contractile vSMCs, disappears dur-
ing active growth.71 On day 10 to 14 an irregular neo-intima becomes evident that can persist in the 
collateral or even lead to complete obliteration of the vessel promoting the previously mentioned prun-
ing. vSMC layers start to revert to the contractile phenotype whereas the ECs still show synthetic ac-
tivity. The lamina elastica interna, restored up to seven layers of vSMCs, can be found in the remod-
eled vessel. Growth has been described to be almost complete after 21 days.51 
 
 
 INTRODUCTION  
 
 12 
 
4 THE TRANSCRIPTION FACTOR EARLY GROWTH RESPONSE (EGR1) 
It requires a good coordination to control leukocyte recruitment and vascular cell proliferation within 
this puzzling disarrangement. Transcription factors (TF) interconnect upstream and downstream sig-
nals. In previous studies transcriptional regulators like activator protein 1 (AP-1)72 or cardiac ankyrin 
repeat protein (carp)73 were found upregulated in arteriogenesis. In this study the murine TF Egr1 was 
investigated to acquire new insights into the molecular regulation of arteriogenesis. Initially, the mu-
rine Egr1 was discovered in murine PC12-cells after stimulation with neuronal GF (NGF). It was 
therefore labeled as nerve GF inducible A (NGFI-A).74 Later it was also referred to as Zif268,75 TIS8 
or krox-24.76 The name early growth response 1 was eventually established by Sukhatme et al during 
studies on stimulated murine and human fibroblasts.77 Egr1 was found to be rapidly and transiently 
expressed in response of a heterogenic group of stimuli like GFs, shear stress, hypoxia, (reperfusion) 
injury and oxidative stress,78, 79, 80 and therefore participates in an array of signal transduction net-
works upstream and downstream.76 
4.1 Structural properties 
The murine Egr1 gene consists of two exons and a 700bp intron (between nucleotide position 556 and 
557) and maps to 5q23-q31.81 It encodes a Cys2-His2-type of zinc-finger TF with the size of 80-82kDa. 
It has been shown that the EGR1 protein gets posttranslational modificated i.e. phosphorylated78, 82 
with a high turnover (in vitro: 3h detection window).78 
4.1.1 The Egr1 promoter 
In order to understand the regulating mechanism behind Egr1 expression, the murine Egr1 promoter 
has been investigated and several functional elements have been characterized83 (Figure 3). 
 
Figure 3: Functional elements on the murine promoter of Egr1 
There are five serum response elements (SRE) located at the 3’ end of the promoter and next to a 
TATA box (AAATA, located 26 nucleotides upstream of the transcription start site).81 Five E-twenty 
six (Ets) family transcription factor-binding sites are arranged adjacently to these SREs indicating 
mutual activation. Furthermore, two cyclic adenosine monophosphate (cAMP) response elements 
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(CREs), an APETALA1 (AP-1) and two gene-specific activator protein 1 (Sp-1) binding sites are lo-
cated on the promoter.84 A GC-rich promoter sequence (GCG(G/T)GGGCG),75 the typical target se-
quence of the EGR1 protein and therefore named early growth response binding-sequence (EBS), can 
also be found,85 making EGR1 capable of binding to its own promoter. Although binding to an EBS 
actually leads to transcriptional activation of other target genes, EGR1 has been shown to downregu-
late its own expression in form of a negative feedback loop by binding to its very own EBS.86 So it 
appears that there is a lot of own transcriptional control regulating EGR1 expression on the RNA and 
protein level therefore providing a fine balanced expression profile.  
4.1.2 The EGR1 protein 
The encoded murine EGR1 protein consists of 533 amino acids and possesses functionally independ-
ent components (Figure 4). The human EGR1 protein is only slightly larger comprising 543 amino 
acids but does not differ significantly concerning amino acid sequence or structural properties.  
 
Figure 4: Functional domains of the murine EGR1 protein  
Serine/threonine as well as proline/serine/threonine rich sequences are located at the N- and the C-terminal re-
gion, respectively. Ser/thr residues are posttranslational phosphorylated. Nuclear translocation is mediated by a 
bipartite NLS that comprises basic residues in the DBD. NAB regulates EGR1 activity by binding to the re-
pressor domain.  
 
The hallmark of TFs is the DNA binding domain (DBD) to adhere to a specific sequence on the DNA 
thus regulating transcription. The DBD, from amino acids 331 to 419, is characterized by three zinc-
finger motives87 that characteristically bind to the EBS.78 Each zinc finger consists of an antiparallel ß 
sheet and an α−helix arranged around the zinc ion.87 Nuclear magnetic resonance studies revealed that 
the zinc fingers are sterically arranged in a semicircular (C-shaped) way thereby fitting into the major 
groove of DNA where each finger binds to 3bp subsite along one strand of the DNA (the G rich 
strand)87 Once synthesized, the EGR1 protein is translocated into the nucleus.78 It therefore holds a 
bipartite-type nuclear localization sequence (NLS), 15 amino acids (amino acids 315-330) on the DBD 
N-terminal flanking region and within the DBD (amino acids 361-419).88 Basic residues characterize 
the NLS.89 The flanking sequence together with all three zinc fingers promotes nuclear localization of 
the EGR1 protein.88 The N-terminal region of the protein is an activation domain (3-281) rich in serine 
and threonine (30%) that can be phosphorylated.78, 82 This large domain is capable of activating tran-
scription 100-fold. The C-terminal holds a second but weaker activation domain containing additional-
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ly proline.89There is also a repressor domain, amino acids 281 to 314, where nuclear co-repressors, 
called NGFI-A binding protein (NAB), adhere to and therefore negatively regulate transcriptional 
activity of the Egr1 gene.90, 91 Two different NABs 1 and 2 have been identified in this context.90, 91 
NAB-2, a “late” early response gene, is induced via the same stimuli91 that activate Egr1 expression, 
but is time-staggered to the latter. EGR1 itself strongly induces expression of the NAB-2 gene by 
eleven EBS that have been identified in the NAB-2 promoter region.92 Therefore, any upregulation of 
Egr1 eventually leads to NAB-2 mediated EGR1 protein repression. NAB-2 effects on Egr1 function 
are quite well investigated in GF induced proliferation.93 FGFs are potent Egr1 activators. However, 
FGF-23 induces NAB-2 at the same time, which eventually suppresses EGR1 mediated transcription 
activity within the nucleus.94 Furthermore, a reciprocal expression pattern for NAB-2 and Egr1 has 
been described; apparently, EGR1 itself prevents an exceeding expression of its own downstream tar-
get genes via repressors like NAB-2.92  
4.2 Function and associated downstream targets 
Egr1 has been quite extensively investigated, though mainly in vitro and in fact, very little is known 
about its interaction with other Egr family members. Egr1 participates in growth, cell survival pro-
grams and apoptosis. Hence, GFs have been shown to induce Egr1 expression. EGR1 again, positively 
regulates expression of many GF genes by binding to the EBS on their promoters and has also been 
shown to act as an important cell cycle regulator, controlling mitose progression.78, 95 EGR1 has previ-
ously been described as a master switch for arteriogenesis in mice and rats after femoral artery exci-
sion,96 and it was shown that adenoviral mediated EGR1 delivery improved perfusion recovery97, 
however the molecular mechanisms behind this role have not been characterized so far. It has been 
shown that mechanical forces such as FSS are capable of increasing the mRNA of EGR1 in cultured 
human ECs via MEK/ERK1/2 after 30min of exposure.50 Cardiac ankyrin protein (carp), described to 
be upregulated during arteriogenesis in vivo, was also shown to induce Egr1 mRNA via MEK/ERK in 
vitro.73 The relation between Egr1 activity and monocyte/macrophage function has also been dis-
cussed. Cellular differentiation along the macrophage lineage is an important task of EGR1.98, 99 Also, 
EGR1 participates in lipopolysaccharide (LPS) - mediated monocytic activation via MEK/ERK 1/2.100 
Moreover, EGR1 was shown to bind to the promoter of uPA in vitro101 and promoter characteristics of 
uPA102 suggest that EGR1 might also be regulating uPA in vivo. Due to the expression profiles of 
MCP-1 and ICAM-1 in vivo,103 these genes are likely EGR1 downstream targets. Cell culture studies 
revealed that the cell cycle regulator cyclin D1, a key regulator during mitotic progression from G1- to 
S-phase, is among the genes lying downstream of Egr1.104 However, cyclin D1 expression was not 
impaired in Egr1 deficient mice after partial hepatectomy and therefore these results could not be con-
firmed in vivo.95 Moreover, there is increasing evidence that Egr1 controls vSMC proliferation. Small 
interfering RNA (siRNA) molecules targeting the coding region of Egr1 attenuated vSMC prolifera-
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tion.105 As stated before, vSMC phenotype switch is a prerequisite for proliferation and is character-
ized by downregulation of αSM-actin70, 71 and SF-1.69 A recent in vitro study showed that downregula-
tion of the latter might be regulated by Egr1.69, 106 Due to its likely involvement in shear response leu-
kocyte recruitment and vSMC proliferation Egr1 is a specifically interesting candidate to study in 
arteriogenesis in vivo. 
4.3 The EGR-family  
Egr1 forms a family of Egr TFs together with three other members, Egr2, Egr3 and Egr4. The EGR2 
and EGR3 proteins, but not EGR4, also contain a NAB binding site. A 90% homologous three tandem 
repeat zinc finger domain characterizes this family and differences among them are found mainly out-
side the DNA binding site.107, 108 It appears that all Egr-TFs are capable of binding to the EBS on the 
promoter of target genes to regulate their expression. This raises the question of a possible compensa-
tory mechanism between the Egr family members.  
An increasing body of evidence is unraveling the distinct functions of the other factors. Egr2 was 
shown to regulate hindbrain segmentation and Egr2 deficient mice were reported to be perinatally 
lethal due to myelination defects in the peripheral nervous system.109 Egr3 deficient mice are viable 
but also display various neuronal defects due to Egr3’s prominent role in the development of muscle 
spindles.110 Egr2 and Egr3 both participate in immunological self-tolerance via T-cell anergy induc-
tion111 and act contrariwise to EGR1 and NAB-2 function in vivo in T-cell mediated autoimmune dis-
ease with Egr3 lying upstream of Egr2.112 On the other hand, a generated conditional Egr2 knockout 
(floxed Egr2 allele)113 has recently been evaluated for CD4 T-cell function and the data suggests that 
T-cell function might be entirely independent from Egr2 function.114 It remains therefore to be clari-
fied, whether these results are due to compensatory mechanisms that have not been evaluated in this 
study. Egr3 has been shown to respond to similar stimuli like Egr1. A recent publication115 investigat-
ed the expression of Egr1/3 in human endothelial cells and found that both can be upregulated via 
VEGF. Interestingly, Egr3 upregulation was found higher and more prolonged than Egr1 and Egr3 
was shown to mediate leukocyte adhesion and angiogenesis.115 The differences in the response to 
VEGF were due to different upstream signaling cascades being involved in Egr3 and Egr1 expression, 
respectively. Publications on Egr4 are still very few available. From what is known Egr4 seems to play 
a crucial role in the developing testis116, 117 and in male fertility in general, as seen in Egr4 deficient 
mice.118 Interestingly, it has been shown that the compensatory function of Egr4 is the reason for fertil-
ity of male Egr1 deficient mice119 in contrast to the observed infertility in female Egr1-/- mice.120 So it 
seems, that the other Egr-family-members, which also bind to the EBS, might take over some but not 
all functions of Egr1 and vice versa, but this hypothesis that Egr2 - 4 might be capable to substitute 
Egr1 function has been proposed but never entirely proven. 
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II.  OBJECT OF THE STUDY 
 
The aim of the study was to provide new insights into the molecular mechanisms of arteriogenesis 
with the main objective to characterize the functional role of Egr1 in a murine model of peripheral 
collateral artery growth employing WT and Egr1-/- mice.  
The first part of this study aimed to focus on the overall importance of Egr1 for arteriogenesis in 
vivo and its expression in growing collateral arteries. Egr1 has been identified as a “master switch” for 
arteriogenesis in a murine model of femoral excision,96 where ischemia and arteriogenesis take place 
not only at the same time but also in the same anatomical area. Therefore, it has not been investigated, 
if and how exactly Egr1 furthers the process of collateral artery growth. In order to answer this ques-
tion, analyses of the Egr1 expression on the RNA and protein level in wildtype animals should be con-
ducted.  
The scope of the second part should be dedicated to leukocyte and especially monocyte recruitment 
in WT and Egr1 deficient mice. Monocyte-counts under baseline conditions and after femoral artery 
ligation should be counted. The putative Egr1 downstream genes MCP-1 as well as ICAM-1 and uPA 
were planned to be analyzed via quantitative real-time polymerase chain reaction (qRT-PCR) to inves-
tigate first of all, whether the expression of these genes was regulated by Egr1 and second of all, 
whether Egr1 deficiency had an impact on monocyte recruitment under baseline conditions and after 
femoral artery occlusion. 
In the third part, the gene expression of other members of the Egr-family were planned to be ana-
lyzed, of which very little is known in the literature. The role of Egr2, -3 and -4 similarly to Egr1 in 
WT mice has never been characterized in arteriogenesis. It was unclear whether the potential activa-
tion of other members was dependent on presence and functionality of EGR1. 
The last part should focus on the influences of EGR1 on vascular cell proliferation in growing col-
lateral arteries. The potential participation of key regulators of proliferation such as cdc20 and cyclin 
D1/E, described as downstream genes of Egr1 in vitro could play an important part during arteriogene-
sis in vivo. Moreover, the expression of the EGR1 repressor NAB-2 was planned to be evaluated in 
this context. The critical vSMC phenotype switch is characterized by downregulation of αSM-actin 
and the transcriptional repressor SF-1 to further vSMC proliferation. The relationship between Egr1 
and the latter two genes has also never been evaluated in vivo. 
Taken together this study is conducted to better understand the molecular mechanisms regulating arte-
riogenesis in terms of monocyte recruitment and cell proliferation as well as the potential of other Egr-
family members to compensate for Egr1 deficiency.  
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III. MATERIALS AND METHODS 
 
1 MATERIALS 
1.1 Mice strains 
1.1.1 C57Bl/6N  
C57Bl/6N mice were purchased from Charles River WIGA Deutschland GmbH, Sulzfeld, Germany. 
Male mice at the age of 8-10 weeks were used as controls with an average weight of 20-25g. These 
mice were used for practicing the surgical procedures and later for timeline expression studies. 
1.1.2 Egr1-/-  
20 male Egr1-/- mice (B6.129-Egr1 (tm1) Jmi N12) at the age of 6-13 weeks with an average body 
weight of 20-25g were purchased from Taconic Europe, Tornbjerg, Danmark. This strain was devel-
oped in the laboratory of Jeffrey Milbrandt121 on a 129S6 background and backcrossed to a C57Bl/6N 
strain for at least 12 generations. Since wild type littermates were not available at Taconic, we com-
pared the results with 20 male wild type C57Bl/6N mice, declared as cage mates by Taconic, with the 
same age and weight. 
1.2 Surgical instruments and expendable material 
All surgical instruments Fine Science Tools (FST), Heidelberg, Germany 
Bepanthen® eye- and nasal ointment Bayer AG, Leverkusen, Germany 
Bode Cutasept® F 250ml spray Bode Chemie GmbH, Hamburg, Germany 
CaliBRITETM beads (unlabeled, FITC, PE) BD Becton Dickinson GmbH, Heidelberg, Germany 
Disposable scalpels (type 20) Feather Safety Razor Co., Osaka, Japan 
Eppendorf tubes 1.5ml Eppendorf AG, Hamburg, Germany 
Ethicon Vicryl® 6-0 Johnson & Johnson GmbH Norderstedt, Germany 
Falcon cell strainer nylon 70µm  BD Becton Dickinson GmbH, Heidelberg, Germany 
Falcon tubes 40ml BD Becton Dickinson GmbH, Heidelberg, Germany 
Filter paper Whatman GmbH, Dassel, Germany 
Fine bore polyethylene tube (58mm/96mm) Smiths Medical International Ltd, Hythe, Kent, UK 
LightCycler® capillaries (20ml) Roche Diagnostics GmbH, Mannheim, Germany 
Lysis Tubes P Analytik Jena (bio solutions), Jena, Germany 
MaXtract High Density 200x 2ml tubes Quiagen GmbH, Hilden, Germany 
Microtiter plate (96-well) Quiagen GmbH, Hilden, Germany 
Nitrocellulose membrane Whatman GmbH, Dassel, Germany 
Nunc CryoTubeTM vials 1,8ml Fisher Scientific GmbH, Schwerte, Germany 
Pipette tips Eppendorf GmbH, Hamburg, Germany 
Shandon cover plates Thermo Fisher Scientific Inc., Waltham, MA, USA 
Silk braded suture (metric 1 US 5/50) Pearsalls Ltd., Taunton, UK 
Sterile cannulas (3G11/4“ and 20G11/2“) BD Becton Dickinson GmbH, Heidelberg, Germany 
Sterile syringes (1 and 5ml) BD Becton Dickinson GmbH, Heidelberg, Germany 
Sutupak Perma Hand®-Silk Suture 4-0 Johnson & Johnson GmbH, Norderstedt, Germany 
Three-way stop cocks B.Braun, Melsungen AG, Germany 
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1.3 Chemicals and special equipment 
 
1st Strand cDNA Synthesis Kit  Roche Diagnostics GmbH, Mannheim, Germany 
Acetone Merck KGaA, Darmstadt, Germany 
Adenosine Fluka Chemie, Buchs, Switzerland 
Agarose, LE, analytical grade Promega GmbH, Mannheim, Germany 
BCA Protein Assay Kit Thermo Fisher Scientific, Bonn, Germany 
Bovine serum albumin (BSA) Sigma Aldrich GmbH, Seelze, Germany 
Blotting grade non-fat–dry milk  Bio-Rad Laboratories GmbH, Munich, Germany 
Bromphenol blue sodium salt Sigma Aldrich GmbH, Seelze, Germany 
Chloroformisoamylalcohol (25:24:1)  Sigma Aldrich GmbH, Seelze, Germany 
Collagenase II GibcoBrl, Invitrogen, Karlsruhe, Germany 
Complete Mini Protease Inhibitor Cocktail  Roche Diagnostics GmbH, Mannheim, Germany 
D*Sucrose  Fluka Chemie GmbH, Buchs, Switzerland 
3,3′-diaminobencidine (DAB)  Sigma Aldrich Chemie GmbH, Munich, Germany 
Dispase GibcoBrl, Invitrogen, Karlsruhe, Germany 
Dithiothreitol (DTT) AppliChem GmbH, Darmstadt, Germany 
6x DNA loading dye Fermentas GmbH, St. Leon-Rot, Germany 
dNTP Mix (10mM each) Eppendorf AG, Hamburg, Germany 
Ethylenediaminetetraacetate (EDTA)  AppliChem GmbH, Darmstadt, Germany 
Ethyleneglycoltetraacetate (EGTA)  Sigma Aldrich Chemie GmbH, Munich, Germany 
Formaldehyde 37% Sigma Aldrich Chemie GmbH, Munich, Germany 
GelRed Nucleic Acid Stain, 10000x in DMSO Biotrend, Chemikalien GmbH, Köln, Germany 
GeneRuler™ 100 bp DNA Ladder Fermentas GmbH, St. Leon-Rot, Germany 
Glycerol 100% solution AppliChem GmbH, Darmstadt, Germany 
Glycine  AppliChem GmbH, Darmstadt, Germany 
Guanidine thiocyanate AppliChem GmbH, Darmstadt, Germany 
HCL 1M  Merck KGaA, Darmstadt, Germany 
Hyaluronidase Sigma Aldrich Chemie, Taufkirchen, Germany 
Isopropanol  Sigma Aldrich GmbH, Seelze, Germany 
Laemmli buffer (10x)  Serva Electrophoresis GmbH, Heidelberg, Germany 
Latex, flexible mold compound  Chicago latex, Crystal Lake, IL, USA 
2-Mercaptoethanol  Sigma Aldrich GmbH, Seelze, Germany 
Methanol  AppliChem GmbH, Darmstadt, Germany 
Methylbutane Sigma Aldrich Chemie GmbH, Munich, Germany 
NaOH 1M   Merck KGaA, Darmstadt, Germany 
N-Laroylsarcosine sodium salt Sigma Aldrich GmbH, Seelze, Germany 
Normal goat serum Vector, Burlingame, CA, USA 
PageRulerTM Prestained Protein Ladder  Fermentas GmbH, St. Leon-Rot, Germany 
Paraformaldehyde 4%  AppliChem GmbH, Darmstadt, Germany 
Phenol Sigma Aldrich GmbH, Seelze, Germany 
Phenylmethanesulfonyl fluoride (PMSF)  Calbiochem, La Jolla CA, USA 
Ponceau S Solution  Sigma Aldrich Chemie GmbH, Munich, Germany 
Potassium chloride (KCL) Merck KGaA, Darmstadt, Germany 
Potassium dihydroxyphosphate (KH2PO4) Merck KGaA, Darmstadt, Germany 
Random nonamers Hoffmann- La Roche, Mannheim, Germany 
RBC Lysis buffer eBiosciences, Frankfurt, Germany 
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RQ1 RNase-Free DNase 1000U, 1U/µl Promega GmbH, Mannheim, Germany 
Sodium acetate Sigma Aldrich GmbH, Seelze, Germany 
Sodium citrate tribasic dihydrate Sigma Aldrich GmbH, Seelze, Germany 
Sodium chloride (NaCl) Sigma Aldrich GmbH, Seelze, Germany 
Sodium dodecyl sulfate (SDS) AppliChem GmbH, Darmstadt, Germany 
Sodium fluoride (NaF) Sigma Aldrich Chemie GmbH, Munich, Germany 
Sodium hydrogen phosphate (Na2HPO4) Merck KGaA, Darmstadt, Germany 
Sodium orthovanadate (Na3VO4) Sigma Aldrich Chemie GmbH, Munich, Germany 
SSYBR Green I Kit, Light Cycler® -  
FastStart DNA MasterPlus 
Hoffmann- La Roche, Mannheim, Germany 
SuperSignal West Femto Maximum  
Sensitivity Substrate 
Thermo Fisher Scientific, Bonn, Germany 
ToPro3 nucleus dye Invitrogen GmbH, Darmstadt, Germany 
TAE 50x Eppendorf AG, Hamburg, Germany 
Tris-buffer AppliChem GmbH, Darmstadt, Germany 
Tris-glycine Gel 4-20%  Serva Electrophoresis, Heidelberg, Germany 
Triton X-100 Sigma Aldrich GmbH, Seelze, Germany 
Tween 20  AppliChem GmbH, Darmstadt, Germany 
1.4 Pharmaceuticals 
Drug Brand name Company 
Atipamezolhydrochloride Revertor® CP-Pharma GmbH, Burgdorf, Germany 
Buprenophine Temgesic® Essex Pharma GmbH, Munich, Germany 
Fentanyl Fentanyl-Curamed® CuraMED Pharma, Karlsruhe, Germany 
Flumazenil (0.5mg/5ml) Flumazenil-hameln® Hameln Pharma GmbH, Hameln,  
Germany 
Heparin-Na 25.000 I.E./5ml Heparin-natrium-25000-
ratiopharm® 
Ratiopharm GmbH, Ulm, Germany 
Isoflurane Forene® Dräger Medical, Lübeck, Germany 
Ketamine hydrochloride Ketavet® Pfizer/ Pharmacia GmbH, Karlsruhe,  
Germany 
Medetomidine-  
hydrochloride 
Dormitor® Pfizer Pharma, Berlin, Germany 
Midazolam Midazolam-ratiopharm® Ratiopharm GmbH, Ulm, Germany 
Naloxone hydrochloride 
(0.4mg/ml) 
Naloxon Inresa Inresa Arzneimittel GmbH, Freiburg, Ger-
many 
Xylazine 2% Rompun® Bayer AG, Leverkusen, Germany 
Table 1: List of pharmaceuticals used in this study 
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1.5 Primers for qRT-PCR 
 
All primers (salt free) were purchased from eurofins mwg operon, Ebersberg, Germany and ordered 
via the website: www.eurofinsdna.com/home.html 
 
Target Primer Sequence Product length, 
annealing temp. 
Egr1 
 
Forward 
Reverse 
5’-CGAACAACCCTATGAGCACCTG-3’ 
5’-CAGAGGAAGACGATGAAGCAGC-3’ 
 270bp, 64oC 
Egr2 
 
Forward 
Reverse 
5’-CGTATCCGAGTAGCTTCG-3’ 
5’-GATACCTTCTGGATAGCAG-3’ 
 116bp, 56oC 
Egr3 
 
Forward 
Reverse 
5’-CAGATGGCTACAGAGAATG-3’ 
5’-CACTCATGAGGCTAATGATG-3’ 
 181bp, 54oC 
Egr4 
 
Forward 
Reverse 
5’-GACTTAACAGACTCCTGC-3’ 
5’-CAGACATGAGGTTGAGAG-3’ 
 136bp, 56oC 
MCP-1 
 
Forward 
Reverse 
5’-CTCAAGAGAGAGGTCTGTGCTG-3’ 
5’-GTAGTGGATGCATTAGCTTCAG-3’ 
 182bp, 62oC 
ICAM-1 
 
Forward 
Reverse 
5’-GAAGTCTGTCAAACAGGAG-3’ 
5’-CAGTACTGGCACCAGAATG-3’ 
 142bp, 58oC 
uPA 
 
Forward 
Reverse 
5’-CTGCTATCATGGAAATGGTGACTC-3’ 
5’-CTAGGCTAATAGCATCAGGTCTG-3’ 
 136bp, 62oC 
cyclin D1 
 
Forward 
Reverse 
5’-GAAGGAGACCATTCCCTTGA-3’ 
5’-GTTCACCAGAAGCAGTTCC-3’ 
 100bp, 60oC 
cyclin E 
 
Forward 
Reverse 
5’-CTCGGGTGTTGTAGGTTGCT-3’ 
5’-CTGTTGGCTGACAGTGGAGA-3’ 
 111bp, 63oC 
cdc20 
 
Forward 
Reverse 
5’-GAGCTCAAAGGACACACAGC-3’ 
5’-GCCACAACCGTAGAGTCTCA-3’ 
 99bp, 62oC 
ki67 Forward 
Reverse 
5’-GAGTGAGGGAATGCCTATG-3’ 
5’-GCTGTGAGTGCCAAGAGAC-3’ 
 145bp, 58oC 
SF-1 
 
Forward 
Reverse 
5‘-CAACGCCAAGATCATGATTC-3‘ 
5‘-CTCCATCGTATTGGCAGTG-3‘ 
 127bp, 56oC 
aSM-actin 
 
Forward 
Reverse 
5’-GAGCATCCGACACTGCTG -3’ 
5’- GTACGTCCAGAGGCATAG -3’ 
 146bp, 58°C 
18S 
 
Forward 
Reverse 
5‘-GGACAGGATTGACAGATTGATAG–3‘ 
5’-CTCGTTCGTTATCGGAATTAAC–3‘ 
 108bp, 64oC 
Table 2: List of primers and their corresponding product length and annealing temperature 
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1.6 Special buffers and solutions 
Adenosine buffer (IHC) 
100ml PBS 
250mg BSA 
100mg adenosine                        pH 7.4 
 
Loading buffer (WB) 
250mM Tris (12.5ml) pH 6.8    
8% SDS (20ml)     
100% glycerol (20ml)     
0.02% bromphenol blue (10mg)   
400mM mercaptoethanol (1.7ml)    
 
Phosphate buffered saline (PBS) 10x  
80g NaCl 
2g KCL 
14.4g Na2HPO4 
2.4g KH2PO4 
aqua dest ad 1L                         pH 7.4 
 
Probe buffer PBS+BSA 2% (WB) 
45ml aqua dest. 
5ml 10 x PBS 
1g BSA 
 
Protein isolation buffer (WB) 
20mM Tris–HCl 
250mM sucrose 
1mM EDTA  
1mM EGTA 
1mM DTT 
0.1mM Na3VO4 
10mM NaF  
0.5mM PMSF                         pH 7.4 
 
Sodium acetate solution (RNA isolation) 
2M Na-acetate (NaCH3COO) (16.4 g) 
dH2O ad 100ml                         pH 4.0 
 
Solution A (RNA isolation) 
50ml dH2O   
4M guanidine thiocyanate (23.63g)  
25mM sodium citrate tribasic dihydrate (367.6 mg) pH 7.0 
0.5% N-lauroylsarcosine sodium salt (0.25g) 
0,1M 2-mercaptoethanol (348.7 µl)               
 
Solution for muscle tissue digestion (FACS) 
Collagenase II 1mg/ml  
Hyaluronidase 0.5mg/ml 
Dispase 1mg/ml 
BSA 0.6mg/ml  
PBS ad 50ml                         pH 7.4  
10x TBS (WB) 
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24.2g Tris 
80g NaCl 
165ml HCL 1N 
835ml aqua dest.                        pH 7.6 
 
Transfer buffer (WB) 
2.9g glycine 
5.8g Tris 
0.37g SDS 
200ml methanol 
aqua dest ad 1L                         pH 8.3 
 
Washing buffer (WB) 
1x TBS 
0.1% Tween-20 
 
 
1.7 Antibodies 
Tables 3 and 4 display the primary and secondary antibodies, respectively, as well as their dilution and 
the application for which they have been used. 
1.7.1 Primary antibodies 
Target Dilution/Application Company 
Rabbit anti-mouse-EGR1  1:500 (WB) 
1: 50 (IF) 
Santa Cruz Biotechnology, Heidelberg, 
Germany 
Mouse anti-mouse αSM-actin 
(clone:1A4) 
1:200 (IF) Abcam, Cambridge, MA, USA 
Rat anti-mouse Mac-3 mAb 
(Clone: M3/84) 1: 100 (IHC) 
BD Pharmingen™, Heidelberg,  
Germany 
anti-mouse CD11b mAb Phyco-
erythrin (PE)-conjugated  
1:10 
5µl in 50µl (FACS) 
Beckman-Coulter, Krefeld, Germany 
anti-mouse CD45 mAb-FITC-
conjugated 
1:10 
5µl in 50µl (FACS) 
Beckman-Coulter, Krefeld, Germany 
Anti-mouse CD3 mAb, FITC-
conjugated 
1:10 
5µl in 50µl (FACS) 
Beckman-Coulter, Krefeld, Germany 
Anti-mouse-CD19 mAb PE-
conjugated 
1:10 
5µl in 50µl (FACS) 
Beckman-Coulter, Krefeld, Germany 
Table 3: List of conjugated and unconjugated primary antibodies, their dilution and application 
(WB = Western Blot, IF = immunofluorescence, IHC =conventional immunohistochemistry, FACS = fluores-
cence activated cell sorting, mAb = monoclonal antibody) 
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1.7.2 Secondary antibodies 
Target Dilution/ 
Application 
Company 
Alexa Fluor®546 goat anti-mouse IgG 
(H+L)  
1:200 (IF) Invitrogen GmbH, Darmstadt, Germany 
Alexa Fluor® 488 goat anti-rabbit IgG 
(H+L) 
1:200 (IF) Invitrogen GmbH, Darmstadt,  
Germany 
Donkey anti-rat IgG HRP conj. 1: 500 (IHC) Dianova GmbH, Hamburg, Germany 
Goat-anti-rabbit-IgG HRP conjugated  1:5000 (WB) Santa Cruz Biotechnology, Heidelberg, 
Germany 
Table 4: List of secondary antibodies, their dilution and application 
1.8 Devices 
All pipettes Eppendorf AG, Hamburg, Germany 
BioPhotometer Eppendorf AG, Hamburg, Germany 
CM 3000 cryomicrotome  Leica GmbH, Wetzlar, Germany 
Confocal microscope Leica TCS SP5 Leica GmbH, Wetzlar, Germany 
Electrophoresis power supply E301 Amersham Biosciences GmbH, Freiburg, Germany 
ELISA Plate Reader Bio-Tek instruments, Winooski, USA 
FACS CaliburTM BD Becton Dickinson GmbH, Heidelberg, Germany 
Heating pad and rectal probe FHC, Bowdonham, ME, USA 
Incubator Haraeus, Hanau, Germany 
Laser Doppler Imager LDI2 V5.1 Moor Instruments Ltd., Devon, UK 
Light Cycler 1.5 Roche Diagnostics GmbH, Mannheim, Germany 
Magnetic stirrer  IKA®-Werke GmbH & CO. KG, Staufen, Germany 
Micro 200 R centrifuge Hettich Zentrifugen, Tuttlingen Germany 
Microinjection syringe Hamilton Bonaduz AG, Bonaduz, Switzerland 
Microwave Siemens AG, Munich Germany 
Orca CCD Camera Hamamatsu PHOTONICS GmbH, Herrsching, Germany 
Speed mill  Analytik Jena (bio solutions), Jena, Germany 
Stereomicroscope DV4 Spot –  
with cold light source KL1500 LCD 
Carl Zeiss AG, Göttingen, Germany 
Thermomixer compact  Eppendorf GmbH, Hamburg, Germany 
1.9 Software 
Adobe® Acrobat ® Professional Adobe Systems Inc., San Jose, Ca, USA 
Endnote® X4.01 Thomson Reuters, New York, NY, USA 
FACSComp software BD Becton Dickinson GmbH, Heidelberg, Germany 
Leica Application Suite AF lite Leica GmbH, Wetzlar, Germany 
Light Cycler Data Analysis  
(Version 3.5.17) 
Hoffmann- La Roche, Mannheim, Germany 
Microsoft® Excel®, Word® 
PowerPoint® 2003  
Microsoft Corp., Redmond, Washington, USA 
Moor LDI2 V5.1 software Moor Instruments Ltd., Devon, UK 
Sigma Plot® 11.0 Systat software inc., Chicago, IL, USA 
Wasabi software Hamamatsu PHOTONICS GmbH, Herrsching, Germany 
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2 METHODS 
2.1 Animal model  
All animal experiments were conducted according to the German law of animal protection and were 
approved by the Government of Oberbayern, Munich, Germany. Only mice were used for experiments 
in this thesis. After arrival at the institute, all mice were kept in standardized cages with a regular 12h 
day and night cycle and received food and water ad libitum.  
2.1.1 Anesthesia protocols 
2.1.1.1 Ketamine/ Xylazine 
Ketamine 100mg/ml, Xylazine 2 % and 0.9 % isotonic saline-solution were combined in a 1:1:2 mix-
ture and injected intraperitoneally (i.p.). Initially, this standard anesthesia protocol was used during the 
establishment of the surgical procedures and some pilot experiments. When better anesthesia combina-
tions were available (see below), ketamine/xylazine was not used anymore. 
2.1.1.2 Triple combination anesthesia (MMF)  
The combination of midazolam (5.0mg/kg), medetomidine (0.5mg/kg) and fentanyl (0.05mg/kg) 
(MMF) is a modern anesthesia protocol. The advantages are an improved analgesia and reduced anes-
thesia induced cardiodepression. Furthermore, there is the option to antagonize the narcotics and there-
fore limit the duration of anesthesia by application of flumazenile (0.5mg/kg), naloxone (1.2mg/kg) 
and atipamezole (2.5mg/kg) (FNA). Although the common opinion is to inject anesthesia i.p., I ap-
plied these substances by subcutaneous injection (s.c.) into the skin fold at the neck, which worked out 
extremely well. Here, mice were not subject to the risk of incidental damage of important structures, 
vessels or organs and the induction is not significantly delayed when compared to i.p. injection. Initial-
ly, mice were given a little amount of isoflurane for a short inhaled narcosis (30 sec) to reduce the 
stress of the injection.  
2.1.1.3 Isoflurane/O2 
Isoflurane (1.5Vol%) combined with 100% O2 (1L/min flow) was used for the Laser Doppler perfu-
sion measurements beginning on day 3 and prior to s.c. injection of narcotics (see above). Since anal-
gesia was not necessary for LDI, the good hypnotic potential of isoflurane and the fast induction and 
waking up period made it ideal for this application. 
 
 
 MATERIALS AND METHODS  
 
 25 
2.1.1.4 Postoperative analgesia 
For postoperative analgesia buprenophin (1.2mg/kg per day) was used. Mice received 100µl of bu-
prenophin s.c. 10min prior to ending of general anesthesia as well as on day 1 and 2. 
2.1.2 Femoral artery ligation  
2.1.2.1 General preparation 
Induction of anesthesia was performed by s.c. injection of triple combination anesthesia MMF. Ade-
quate surgical tolerance was established when the toe reflex of both hind limbs could not be triggered 
anymore. In order to protect the eyes from drying-out, bepanthene eye-ointment was then applied to 
the eyes of animals. Subsequently, mice were placed in a supine position on a heating pad and a rectal 
probe was inserted in order to monitor the body temperature and maintain readings of 37°C. Then both 
inguinal skin areas were cleaned with disinfection spray and were cautiously shaved with a scalpel 
blade. 
2.1.2.2 Surgical procedure 
All surgical procedures were conducted using a stereomicroscope and a cold light source. Skin inci-
sions of 5mm were performed on each leg at the inguinal area. The superficial adipose tissue was re-
moved carefully to reach the femoral artery, vein and nerve (Figure 5). 
 
Figure 5: Ligation of femoral artery 
A: Anatomical overview showing the arteria (A.) femoralis & profunda femoris as well as the collateral arteries. 
B: Ligature site: Suture placed between the distal A. genu descendens and the proximal A. circumflexa  
C: View of the nod, the perfusion of the distal part of the femoral artery is suspended. 
 
The latter was dissected from the artery and finally the femoral artery and vein were carefully separat-
ed without producing any bleeding of a vessel. Distal of the branching of the circumflex artery and 
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proximal to the branching of the A. genu descendens, a piece of braded suture (7/0) was placed under 
the femoral artery of both hindlimbs. On the right side, three nods were tied for ligation of the femoral 
artery. On the left side, the sham side, the suture was only placed under the vessel but no nod was tied. 
The suture remained at the site. Finally the skin was sutured using 6/0 Vicryl and anesthesia-
antagonizing mixture FNA was injected into the mice. 
2.1.3 Isolation of tissue  
2.1.3.1 Catheterization of abdominal aorta 
Each blood cell carries a distinct amount of RNA and protein that could naturally “contaminate” the 
gene expression analyses of isolated collateral arteries among animals. Thus, the collateral arteries 
needed to be perfused to reduce the amount of blood inside the vessels before harvesting the tissue at 
different timepoints after femoral artery ligation to prevent this natural bias. Therefore, the aorta cathe-
terization technique was adapted from the arteriogenesis rabbit model and applied to mice (Figure 6). 
 
Figure 6: Catheterization of murine aorta (from top left to lower right) 
The inferior vena cava and the aorta (upper left panel) are mobilized (upper middle panel) and the aorta is sepa-
rated from the vein (upper right panel). A small incision is made (middle left panel) and the catheter is inserted 
(lower left panel) and fixed with a double nod (middle right panel). 
 
The catheter was composed of a piece of tubing (outer diameter: 58mm, inner diameter: 38mm) that 
was placed onto a canula (size 14, tip cut off) connected to a three-way stopcock. Prior to insertion, 
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the catheter was rinsed with 0.9% saline solution. After commencing of the surgical tolerance phase 
by inducing anesthesia with MMF, the mouse was given 0,1ml of heparin and was placed transversely 
on a heating pad monitoring body temperature. A broad midline laparotomy from the xiphoid process 
to pubic area was performed and major parts of the intestine were mobilized and placed on the right of 
the mouse on a gauze compress to gain access to the abdominal aorta and the inferior vena cava. Both 
vessels were loaded on a curved forceps and a piece of Perma Hand silk suture was wound around 
both vessels right below the outlet of both renal vessels. Both ends of the suture were fixed with a 
Halstedt-Mosquito hemostat under cranial traction. The traction is particularly important to reduce 
blood flow and pressure within both vessels in order to facilitate the insertion of the catheter. Next, the 
abdominal aorta is freed from annexing fascia and separated from the inferior vena cava and another 
piece of suture was wound around the vessel and a provisional single nod was tied. Usually, the inferi-
or vena cava ruptures, which is necessary to establish an artificial outflow for the perfusion solution 
and to prevent an overload of volume. Due to the first suture, the bleeding was controllable. Using fine 
spring scissors a small cut was conducted as close as possible to the first suture, the catheter was in-
serted carefully without tearing the aorta and advanced in caudal direction. The provisional nod was 
tied and a second nod placed on top to ensure stable positioning. 
2.1.3.2  Isolation of tissue for qRT-PCR and Western Blot  
After inserting the catheter, the distal vascular system was rinsed with 5ml saline solution until both 
paws appeared to be free from blood. After perfusion, however, the collaterals were hardly distin-
guishable from the surrounding muscle tissue; therefore a contrast medium had to be infused for tissue 
isolation (Figure 7). 
 
Figure 7: Isolation of collaterals for qRT-PCR and Western Blot 
A: Photography showing collaterals perfused with latex.  
B: The two superficial collateral arteries were dissected in a standardized size.  
C: Latex made also a very fine preparation of these collaterals possible  
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Latex has excellent characteristics for this issue. The white color enables a good contrast to the muscle 
and the flexible texture permits the clear preparation of very small arterioles. 1ml was infused slowly 
into the vessels via the lying catheter. After preparation of skin and fascia from both hindlimbs, the 
two superficial collateral arteries were very good visible and easily isolated. Brain tissue and bone 
marrow was harvested 12h after ligation. For bone marrow sampling, both femurs per animal were 
flushed with physiologic saline solution and the cell suspension was collected in Eppendorf tubes. All 
samples were snap frozen in liquid nitrogen and stored at -80°C until further processing for qRT-PCR 
or Western blot. 
2.1.3.3 Tissue sampling for immunohistological analyses 
Three days after femoral artery occlusion, aorta was cannulated as described above and the vascular 
system of both hindlimbs was perfused with 3ml of adenosine buffer. For the detection of macrophag-
es, the vasculature was perfused with 4% PFA to fix the tissue immediately. By touching both legs and 
tail, the grade of fixation could be estimated. After perfusion, the adductor muscles of both hindlimbs 
(occluded and non-occluded) were dissected. The muscles were isolated in a triangle-like shape com-
prising the collateral vessels in the front area. Proximal to the A. profunda femoris the base was cut. 
One side of the tip was cut laterally from the A. femoralis towards the knee and the natural anatomical 
border of the adductor muscle built the third side. Then the samples were placed in a tube containing 
40ml of 10% glucose solution at 4°C over night. This hyperosmotic solution dehydrated the muscles 
and they dropped down to the bottom of the tube. The next day, the tissue was transferred into 40ml of 
20% glucose solution and stored over night at 4°C. For cryopreservation, the muscles were placed 
upright on cork plates, covered with TissueTek® and then frozen immediately in 100ml of cold 
methylbutane (-150°C). This was done to cool down the tissue more slowly and reduce the amount of 
air entrapped. Then the samples were submerged in liquid nitrogen (-180°C) and stored at -80°C. For 
the detection of Egr1, samples without PFA fixative were used. Adductor muscles were harvested after 
perfusion with adenosine buffer placed face down in intermediate sized cryomolds and covered with 
TissuTek®. Samples were frozen on dry ice and stored at -80°C until further processing. 
2.2 Laser Doppler perfusion measurements 
The laser Doppler technique is a commonly used method to measure perfusion in the microcirculation. 
There are basically two principles: first there is the laser Doppler perfusion monitor where optical 
fiber light guides transmit light to the tissue and back to a probe that usually requires direct tissue con-
tact. Second, there is the laser Doppler imaging (LDI) where the tissue remains untouched by the de-
tector. For this study, the moorLDI2 was used to measure perfusion in the right and left leg prior to 
ligation, directly after and on day 3, 7, 14 and 21. Before using the device, I learned the technique at 
the Max-Planck-Institute in Bad Nauheim, Germany and established the method at our laboratory. 
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2.2.1 Technical background 
The LDI equipment consists of a laser head that generates a low power laser beam in conventional 
technique via stimulated emission in an optic resonator. A moving mirror deflects the emitted beam in 
that way that a single beam is scanning a defined area in this study both mice hind limbs. The infrared 
wavelength of the beam does not only penetrate better through darker pigmented skin than a red wave-
length, it also gives a higher weighting to blood flow in the deeper dermis. The laser beam is scattered 
by moving blood in vessels of the hindlimbs and by static tissue. Motion shifts the light in frequency 
(so called “Doppler” effect) whereas static tissue is non-shifting. The difference of shifting and non-
shifting light is detected at two square-law detectors (receiver module) in form of intensity fluctua-
tions, processed and displayed as color-coded pixels (flux image). Flux arbitrary units are proportional 
to the blood flow. Absence of blood flow, however, does not lead to “zero” flux. The residual intersti-
tial movements are detected as well (resting tissue bias) and need to be subtracted during the data 
evaluation (see below).  
2.2.2 Measurements 
Prior to ligation, mice were anesthetized as described above and placed in a supine position (Figure 8).  
 
 
Figure 8: LDI setup 
A: Laser Doppler equipment with a water bath regulating constantly the temperature of a heating chamber un-
derneath the laser beam.  
B: Close up of heating chamber with gas mask for inhalative anesthesia. Distilled H2O was heated in the water 
bath and directed into the chamber using plastic tubing connected to acrylic glass tubes within the chamber.  
C: Positioning of mouse on stage including the facemask. This stage can be moved and is placed inside of the 
heating chamber. 
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2.3 qRT-PCR 
2.3.1 Total RNA isolation 
Total RNA was extracted from isolated collateral arteries according to the single-step method of 
Chomczynski and Sacchi.122 Two isolated collaterals per mouse per side were placed in lysis tubes, 
300µl of solution A was added and the probe was homogenized in a speed mill for two minutes. Sub-
sequently, 60µl 2M sodium acetate (pH 4.0), 600µl phenol and 120µl chloroform/isoamylalcohol 
(49:1 v/v) were added, the probe was vigorously shaken for one minute, transferred into MaXtract 
High Density tubes and placed on ice for 15min. Then the probe was centrifuged at 12000g at 4 °C for 
2 minutes and the supernatant was transferred into a new 1,5ml reaction tube. To remove residual ge-
nomic DNA, 6µl 10x reaction buffer as well as 6µl DNase (both RNase-Free DNase Set) were added 
and the probe was incubated at 37°C for 30 minutes. Phenol and chloroform/isoamylacohol were add-
ed to the probe (49:1 v/v) and again the probe was shaken vigorously for one minute, transferred into 
2ml MaXtract High Density tubes, placed on ice for 15 minutes and centrifuged at 12000g at 4°C for 2 
minutes. The supernatant was transferred into a new 1,5ml tube, 1µl glycogen and 600µl isopropanol 
were added and incubated for 1 hour at -20°C or over night. Then the probe was spun down at 10,000g 
at 4°C for 30min, the pellet washed twice in 70% ice-cold ethanol and again centrifuged at 10,000g for 
five minutes. The resulting pellet was taken up in 90µl of Solution A, resuspended in 90µl isopropanol 
and the probe was kept at -20°C for over at least an hour or over night. After spinning down at 
10,000g for 25 minutes, the pellet was washed two times with 70% ice-cold ethanol and centrifuged at 
10,000g for 5 minutes. The pellet was let dry, then resuspended in 100µl ddH2O and placed in a shaker 
at 64°C for 10-15 minutes. The concentration was determined in 2-4µl aliquots via measurement of 
the optical density (OD) in a spectrophotometer at 260nm (absorption spectrometry) according to the 
formula: 
c(µg RNA/µl H2O) = (OD260*V*F)/1000 
Where: 
c = concentration of undiluted RNA sample 
OD260 = absorption at 260nm  
F = multiplication factor (40 µg/ml for an RNA probe) 
V = dilution factor in sample 
OD260 values in the range of 0.1 and 1.0 were considered reliable.  
 
The purity of the probe (exclusion of contamination) was determined with the OD ratio OD260/OD280, 
absorption values at 260nm and 280nm, and values in the range of 1.8-2.0 were accepted. 
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2.3.2 Agarose gel electrophoresis 
The qRT-PCR product and the quality of total RNA, respectively, were confirmed by gel electropho-
resis on a 1.2% agarose gel using GelRed staining. 1.2g agarose and 100ml 1x TAE buffer were 
placed for 2 min at 600Watt in a microwave, placed on a magnetic stirrer until it was lukewarm. 5µl of 
Gel Red dye was added while stirring. The mixture was filled in the gel chamber and allowed to solid-
ify during 30min at 4°C. 3µl loading dye was added to 10µl of the probe in ddH2O (final volume of 
qRT-PCR products or 1µg of RNA, respectively) and spun down for 1min at 7300g. Probes were care-
fully pipetted in the slots of the gel and 1x TAE was filled in the tank. To evaluate the qRT-PCR gen-
erated DNA amplicon, a 100bp DNA ladder, a negative control (RNA instead of cDNA was used for 
qRT-PCR) as well as ddH2O ran on the gel along with the qRT-PCR products. The gel was allowed to 
run at 70mA//40-60V for 1.5-2h. Documentation was performed using a cooled CCD camera and 
Wasabi software. 
2.3.3 cDNA-Synthesis and qRT-PCR 
1µg of RNA was reverse transcribed into cDNA with random nonamers and the 1st Strand cDNA 
Synthesis Kit for qRT-PCR. 1µg of total RNA was diluted to a Volume of 7.8µl and 12.2µl of the 
reaction kit (Table 4) was added. The reaction kit was composed of the following components: 
Reagent Volume/1 sample Final concentration 
10x reaction buffer 2.0µl 1x 
25mM MgCl2 4.0µl 5mM 
Deoxynucleotide Mix 2.0µl 1mM 
Random Primer p(dN)6 2.0µl 0.08 A260 units (3.2µg) 
RNase Inhibitor 1.0µl  50 units 
AMV Reverse Transcriptase 0.8µl ≥20 units 
Gelatin 0.4µl 0.01mg/ml 
Total 12.2 µl  
Table 5: Reaction mix for cDNA synthesis 
The mixture with the total volume of 20µl was briefly vortexed and centrifuged to collect the sample 
at the bottom of the tube, then the mixture was incubated at 25°C for 10min (annealing), at 42°C for 
60min (reverse transcription), at 99°C for 5min (denaturation of reverse transcriptase) followed by a 
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cooling down at 4°C for 5min. Finally 80µl ddH2O were added to the tube and cDNA was stored in 
eppendorf tubes at -20°C.  
qRT-PCR was performed on a Light Cycler 1.5 using a SSYBR Green I Kit - Light Cycler® FastStart 
DNA MasterPlus in a reaction volume of 10µl according to the manufacturer’s protocol. Each PCR re-
action had a reaction volume of 10µl and was composed according to the manufacturer’s protocol: 
1µl of cDNA,  
1µl of primer mixture (50pmol of each forward and reverse primer), 
2µl “reaction mix” (contains FastStart Taq DNA Polymerase, reaction buffer, MgCl2, SYBR 
Green I dye, dNTP)  
6µl dH2O (PCR grade, provided by the manufacturer) 
Cycling parameters were: 
95°C for 10 minutes (initial denaturation) 
95°C for 10 seconds (40 cycles of denaturation) 
5 seconds of annealing (primer specific temperatures are listed in materials 1.5, table 2), 
72°C for 15 seconds (extension) 
Melting curve: from 65°C to 95°C, ramp rate 0.1°C/sec 
Cooling 30s at 40°C 
At least three independent qRT-PCR reactions were performed on each template. Results were ana-
lyzed using Light Cycler Data Analysis (Version 3.5.17). The specificity of the amplification products 
was confirmed by analyzing their melting curves (no additional peak was visible).  
For generation of a standard curve, dilutions from 105 to 1010 were generated. The resulting slope and 
crossing point (Cp) for targets (CpT) and reference gene (CpR) were established. Slope values were 
used for calculation of efficiency using the following formula: 
E= 10^(-1/slope) 
Since “typical” housekeeping genes like glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
beta3-actin are subject to a greater variance in expression levels dependent on experimental treatment 
conditions and are indeed differentially expressed in this model, they could not serve as internal stand-
ards.123 Therefore, results were normalized to the expression levels of the 18S rRNA123 with the fol-
lowing formula according to the method of method of Pfaffl.124 
ET 
CpT(C) - CpT(S) 
Normalized ratio = 
      ER 
CpR(C) – CpR(S) 
Where: 
ET = Efficiency of target, ER = Efficiency of reference (here: 18S rRNA) 
CpT = Crossing point of target (cycle number at detection threshold) 
CpR = Crossing point of reference (cycle number at detection threshold) 
R = Reference 
S = Sample 
C = Calibrator (tissue from untreated animals was used as calibrator probe) 
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2.4 Western Blot  
2.4.1 Protein isolation and determination of concentration  
To isolate total protein, tissue samples were placed on ice in 3ml total protein isolation buffer and 
homogenized using a Teflon-glass pestle. After incubation of 30min on ice, the probe was centrifuged 
at 14,000g for 30min at 4°C. The total protein concentration was measured in the supernatant using a 
bicinchoninic acid (BCA) assay kit. The assay is based on two reactions. Peptide bonds in proteins 
reduce Cu2+ ions to Cu1+ so that the quantity reduced Cu2+ is proportional to the amount of protein 
present in the solution. Then, two molecules of BCA are able to chelate with one Cu1+ ion thereby 
forming a purple complex that can be detected at the wavelength of 562nm. In order to create a stand-
ard curve for the protein quantification, wells of a 96-well plate were filled with the following concen-
trations of BSA (in mg): 0 (baseline), 0.05, 0.1, 0.25, 0.5, 0.75, 1.0 and 2.0 in a reaction volume of 
10µl. The kit’s reagents were mixed according to the manufacturer’s instructions and 200µl of the 
mixture was added to each well. After incubation of approximately 30min at room temperature, the 
OD562 was measured using the ELISA reader. The OD of the buffer was measured as well to subtract 
its background value from the probe values. The results for BSA were plotted to a standard curve and 
the protein concentration of test samples was determined accordingly. 
2.4.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
4x loading buffer was added to the sample according to the determined concentration of the sample 
(4:1), followed by incubation of 5min at 95°C in a mixer for denaturation of proteins and was then 
placed on ice. Laemmlie buffer was filled in the tank. Equal amounts of probes (10mg) and the molec-
ular weight marker (Page Ruler Prest. Protein Ladder marker) were filled in the slots of a 4–20% Tris-
glycine gel using a Hamilton syringe. The running conditions were 10mA for 10min and subsequently 
25mA for 70-90min (discontinuous method established by Laemmli125). 
2.4.3 Blotting 
For electrophoretic transfer of sample proteins to a nitrocellulose membrane, chromatography filter 
paper and membrane were cut according to the size of the gel (7x8cm). Filter paper, membrane, gel 
and another piece of filter paper were incubated with transfer buffer for 5min and placed in the trans-
fer assembly. Current values were calculated according to the size of the filter paper (I[mA] = A[cm2] 
x 0.8) and the transfer ran for over 1h. After the transfer, proteins were stained with Ponceau S solu-
tion (1:9 dilution in H2O bidest). To do so, the membrane was covered entirely with the working solu-
tion, gently shaken and subsequently the solution removed. Then fresh working solution was added to 
the membrane, placed on a shaker and incubated for 5-10min at room temperature. Finally the mem-
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brane was washed with washing buffer until bands were visible and scanned for documentation. The 
membrane was washed until the bands disappeared, blocked in 5% non-fat dry milk (NFDM) for 1h 
and washed again 3 times (each washing procedure lasted 5min). 
2.4.4 Detection of immunoreactive bands 
For EGR1 protein detection, the polyclonal rabbit anti-mouse- EGR1 antibody was diluted (1:500) in 
5% BSA, added to the blot and incubated over night at 4°C. The next day, the blot was washed 3 times 
with washing buffer for 10min. The secondary HRP-conjugated goat-anti-rabbit-IgG antibody was 
diluted in 5% NFDM (1:5000) and incubated for 1 hour at room temperature followed by washing 
three times (10min each) of the membrane. In the meantime, the chemiluminescent substrate (Super-
Signal-Femto-West) was prepared according to the manufacturer’s protocol. Then the membrane was 
incubated with the substrate (0.1ml/cm2) for 5min to visualize the immunoreactive bands and placed in 
a plastic wrap. The blot was imaged on a cooled CCD camera using wasabi software. Results are dis-
played in concordance with the Ponceau staining since typical housekeeping genes are not applicable 
for this model123. 
2.5 Immunohistochemistry 
2.5.1 EGR1 staining 
7µm sections were cut on a cryomicrotome, placed on SuperFrost Menzel slides, allowed to dry for 
one hour and stored in -80°C until further processing. On the day of the staining, slides were placed in 
ice-cold acetone for 20min for fixation. Then the slides were mounted on Shandon coverplates® in a 
humid chamber and 100µl PBS/0.3%Triton (P/T) (v/v) was added to each slide. Subsequently, slides 
were blocked with 5% normal goat serum in P/T (v/v). Slides were washed once with P/T and then 
incubated with a mixture containing the rabbit anti-mouse EGR1 (1:50) and the anti-aSM Actin anti-
body (1:100) diluted in P/T over night at 4°C. After rinsing for 5min with P/T, the slides were incubat-
ed with a mixture containing the secondary antibodies Alexa fluor488-conjugated goat anti-rabbit and 
Alexa fluor562-conjugated goat anti-mouse IgG (each 1:200 in P/T) for 1 hour at room temperature 
protected from light. Subsequently, the slides were rinsed twice with P/T and incubated with ToPro3 
(1:400) diluted in P/T (v/v) for 10min to stain nuclei. Sections stained whithout the primary or the 
secondary antibody served as negative controls. Slides were removed from the cover plates, and co-
verslipped using Vectastain mounting medium and immediately analyzed on a Leica confocal micro-
scope using the Leica application suite software. 
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2.5.2 Leukocyte quantification  
Histological quantification of the number of activated macrophages in the adductor muscle was per-
formed in Egr1-/- and WT mice (n=3/ per group). From every adductor, 6 cryosections (7µm) were 
obtained; 2 from the medial, 2 from the middle and 2 from the lateral part. The distances between the 
sections remained the same for every sample. Sections were air-dried, washed with PBS, incubated 
with 3ml H2O2 in 180ml methanol (10min) for quenching of endogenous peroxidase activity. For de-
tection of macrophages, slides were incubated with a monoclonal rat anti-mouse Mac-3 antibody (over 
night at 4°C, 1:100) and subsequently incubated with horseradish peroxidase conjugated donkey anti-
rat IgG (1h, 1:200). Again, sections stained whithout the primary or the secondary antibody served as 
negative controls. The immunoperoxidase signal was visualized with the chromogen 3.3′-
diaminobencidine (DAB). The total number of Mac-3 positive cells accumulated in the adventitia and 
perivascular space of collateral arteries was counted per slide.  
2.6 Fluorescence activated cell sorting (FACS) 
2.6.1 FACS-analysis of whole blood 
Whole blood from Egr1-/- and WT mice (n=9 per group) was drawn from the left ventricle by intracar-
diac puncture. Mice under anesthesia were given 0.1ml of heparin (500IU), placed on their back and 
the skin of the thorax was carefully removed. The third or fourth intercostal space was punctured using 
a 1ml syringe and a fine canula. The collected blood was diluted in an equal volume using 0.9% saline 
and red blood cell lysis was performed according to standard protocols. 30µl of the resulting cell sus-
pension was incubated with 10µl of an anti-mouse CD11b PE-conjugated mAb. Before sorting, re-
maining erythrocytes were lysed according to standard procedures (fixation in 2% PFA for 10min and 
incubation with 0.1% Triton X-100 in PBS for 30 minutes at room temperature). Granulocyte and 
monocyte populations were identified by fluorescence and scatter light characteristics. Absolute mon-
ocyte and granulocyte counts were calculated from the numbers of analyzed monocytes and fluores-
cent standard beads that were added to the probe. 
2.6.2 FACS-analysis of the whole adductor muscle 
In order to detect cells within muscle tissue, the adductor muscles of Egr1-/- and WT mice (n=6 per 
group), were perfused with PBS via cannulation of the aorta to eliminate the blood, harvested, 
weighed (each weighed 2mg±0.05) and placed in small cell culture dishes. Next the homogenization 
of the tissue was executed by cutting the tissue into small pieces with a sterile scalpel and by inducing 
digestion with the digestion solution. The dishes were softly shaken and placed in an incubator at 37°C 
for over an hour. In between the suspension was resuspended using a 500µl pipette to facilitate ho-
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mogenization. Then the homogenisate was filtered through a 70µm cell strainer together with PBS and 
2% BSA, spun for 10 min at 95g and the supernatant discarded. The resuspended pellet was washed 
by centrifugation again at 95g for 5min and finally resuspended in 100µl PBS and 2% BSA. The sam-
ples were incubated with one of the following combinations of two monoclonal antibodies: 10µl CD 
11b PE/ CD 45 FITC or CD 3 FITC/ CD19 PE for 20min at 4C°. The solution was washed three times 
by centrifugation at 95g for 5 minutes and finally resuspended in 100µl PBS and 2% BSA. Fluorescent 
standard beads were used to calculate the absolute numbers of cells per µl of cell suspension. 
2.7 Statistical analysis  
Statistical analysis was carried out with SigmaPlot® 11.0. All experimental values are stated as mean ± 
SEM. The data was first tested for normality (Kolmogorov-Smirnov-Test). Analyses between two 
groups were performed using unpaired student’s t-test or Mann-Whitney rank sum test, respectively. 
Analyses between two or more groups were performed using one-way-ANOVA and subsequent Holm 
Sidak correction. Results were considered to be statistically significant with p values of <0.05.  
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IV. RESULTS 
 
1 GENERAL OBSERVATIONS 
Prior to surgery no obvious differences or an apparent phenotype were observed in WT or Egr1 defi-
cient mice. All initial surgical procedures were conducted without complications (arterial, venous or 
neuronal damage) and were well tolerated by Egr1 deficient and control mice; none of the animals 
showed an increased tendency of vessel fragility during the surgical procedure or died during or after 
the procedure. No anatomical variations in the hindlimb vasculature such as differences in branching 
or caliber of the vessels were observed in Egr1 deficient mice when compared to control mice and no 
bleeding occurred. Already 1h after surgery, animals of both groups moved around in cages and start-
ed grooming and cleansing their fur. No wound infections, skin color changes, ischemic gangrenes or 
a significant motor impairment of the hind limbs were observed. Food intake and water consumption 
were normal in both groups. 
2 PARTICIPATION OF EGR1 IN COLLATERAL ARTERY GROWTH 
2.1 Perfusion recovery in wildtype and Egr1 deficient mice 
Egr1 has previously been studied in a femoral artery excision model,96 where angiogenesis and arteri-
ogenesis occur in the adductor muscle at the same time. In order to evaluate the role of Egr1 during 
arteriogenesis only, the unilateral femoral artery ligation model was used in WT and Egr1 deficient 
mice (n=7 per group). The time course of perfusion recovery was monitored by LDI perfusion meas-
urements over the time period of 21 days. Prior to femoral artery ligation (baseline measurement), no 
significant differences in right-to-left blood perfusion ratio between the WT (0.99±0.02) and the Egr1 
deficient group (1.0±0.02) were detected. Immediately after ligation, the blood flow ratio (ligated/non-
ligated) dropped by 90% in both groups with the WT group showing a ratio of 0.11±0.01 and the Egr1 
deficient mice showing a mean value of 0.10±0.02. On day 3, the group of the Egr1 deficient mice 
showed a slight tendency for a delay in perfusion recovery (0.2±0.04) when compared to the WT 
group (0.31±0.03). This difference, however, was not statistically significant (p=0.06). On day 7, sta-
tistically significant differences in Egr1-/- (0.46±0.05) vs. WT (0.73±0.04) became apparent and per-
sisted also at day 14 (0.65±0.02 Egr1-/- vs. 0.88±0.04 WT) and day 21 (0.79±0.03 Egr1-/- vs. 0.96±0.02 
WT), the end of the observation period (Figure 10). 
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Figure 10: LDI analyses in Egr1-/- and WT mice after femoral artery ligation 
Top: Representative laser Doppler images of both groups prior to, directly after ligation and on day 7.  
Bottom: Line plot showing right-to-left (occ/sham) flux ratios during an observation period of 21 days, n=7, 
mean±SEM, *p<0.05 vs. control.  
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2.2 Egr1 expression in arteriogenesis 
The collateral arteries of C57Bl/6 mice were harvested at timepoints 3h, 6h, 12h, 24h, 48h and 3d after 
femoral artery ligation from the occluded and the sham side and qRT-PCR was performed for Egr1 
levels. Quantification in relation to 18S revealed significant differences between the occluded and the 
sham side at 12h, 24h, 36h and 48h. (Figure 11A) Accordingly, protein levels of Egr1 in collateral 
arteries were increased on the occluded side when compared to sham at 24h, 36h and 48h after femoral 
artery ligation. (Figure 11B)  
Figure 11: Egr1 Expression in growing collateral arteries 
A: Vertical bar chart showing the timeline of Egr1 mRNA levels expressed in isolated growing collaterals of WT 
mice at various time points after femoral ligation. Vertical dot line represents Egr1 mRNA levels detected on the 
sham side which was set to 100% to calculate the relative expression, mean±SEM, *p<0.05 vs. sham.  
B: Representative Western Blot of EGR1 protein (top) isolated from collateral arteries 12h, 24h, 36h and 48h 
after ligation. Bottom: Ponceaustaining performed to control equal loading. 
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Immunofluorescence staining for EGR1 48h after femoral artery ligation evidenced a localization of 
EGR1 in ECs, vSMCs and perivascular cells of growing collaterals as well as in venules and nerves 
(Figure 12). When focusing closer on the distinct layers of the arterial collateral vessel, EGR1 stained 
to the activated bulging endothelium and to cells adherent to ECs. Focusing at the smooth muscle cell 
layer, EGR1 co-stained with αSM-actin and was also detected in perivascular cells. 
 
 
Figure 12: Immunohistochemical detection of EGR1 in growing collateral arteries  
Crossectional view of collateral vessels in the adductor muscle 48h after ligation showing single stain (nucleus = 
blue, aSM-actin = red, EGR1= green) and merged images  
A: Overview over collateral artery (A), vein (V) and nerve (N) in a crossection focusing on the endothelial layer: 
EGR1 (green) stains to the activated bulged endothelial of the collateral arteriole and venule (arrows). The insert 
contains a magnification showing nuclei of endothelial cells staining positive for EGR1. EGR1 was also detected 
in nerves and perivascular cells (arrow heads). Scale bar = 50µm 
B: Overview over collateral artery (A), vein (V) and nerve (N) in a crosssection focusing on the smooth muscle 
cell layer: The insert shows a magnification of EGR1 stained to the smooth muscle cell layer together with αSM-
actin (arrows). Scale bar = 50µm 
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3 EGR1 INFLUENCES ON CELL COUNTS AND LEUKOCYTE DISTRIBUTION  
3.1 Leukocyte recruitment  
It has been previously reported that Egr1 deficiency might affect cell maturation and cell numbers; 
however no data on baseline monocyte counts were available for these mice. In order to analyze the 
baseline monocyte and granulocyte counts of Egr1-/- and WT mice, FACS analyses of the whole blood 
in non-ligated animals were performed. The data showed significantly increased amounts of mono-
cytes in Egr1-/- mice (521.89±52.88 cells/µl) when compared to WT mice (326.57±22.04 cells/µl). 
Accordingly, higher amounts of granulocytes were also detected in Egr1-/- mice (811.79±76.96 
cells/µl) compared to the WT group (559.80±34.57 cells/µl) (Figure 13).  
 
Figure 13: Baseline leukocyte counts in Egr1-/- and WT mice 
Vertical bar chart showing FACS blood cell counts of monocytes and granulocytes in WT and Egr1-/- mice; 
mean±SEM, *p<0.05. 
Next, it was investigated whether increased amounts of blood monocytes might as well result in in-
creased numbers of macrophages in the adductor muscle in the baseline situation (sham condition) and 
after imposing a stimulus for transmigration (femoral artery ligation). Therefore adductor muscle tis-
sue samples were collected after femoral artery ligation on the sham and the occluded side. Using im-
munohistochemistry, the number of macrophages accumulated in the perivascular area of growing 
collateral arteries (occluded side) and sham arteries was counted per arteriole per slide. The quantifica-
tion revealed significantly more cells in the perivascular space of the occluded side of Egr1-/- mice 
(8.10±0.99 per vessel) when compared to WT (6.12±0.45 per vessel) 3 days after femoral ligation. 
When the sham sides of both groups were compared, Egr1-/- mice showed significantly fewer macro-
phages (1.87±0.16 per vessel) than WT mice (3.91±0.44 per vessel). These data indicate that mono-
cyte recruitment is significantly impaired in Egr1-/- mice under baseline conditions (Figure 14). 
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In WT mice, Egr2 and Egr3 levels were significantly downregulated at 12h after femoral ligation 
(Egr2: 0.35fold occ vs. sham and Egr3: 0.44fold, respectively). Egr4 mRNA levels evidenced a trend 
towards upregulation on the occluded side; however, no significance could be detected. By contrast, 
Egr1-/- mice displayed a significant upregulation of Egr2 and Egr3 mRNA on the occluded side (Egr2: 
2.14fold occ vs. sham and Egr3: 1.20fold, respectively). Egr4 was found significantly upregulated on 
the occluded side but in collaterals on the sham side, Egr4 was barely detectable via qRT-PCR. 
5 INFLUENCES ON VASCULAR CELL PROLIFERATION 
5.1 Cell cycle progression  
In order to evaluate mitotic progression, mRNA levels of Egr1 downstream genes and important cell 
cycle regulators cyclin D1, E and cdc20 were analyzed by means of qRT-PCR. Cyclin D1, cyclin E 
and cdc20 showed no differential expression pattern in WT mice (Figure 18). In contrast, cyclin E 
(1.3fold) and cdc20 (2.0fold) were significantly upregulated and in growing collaterals of Egr1-/- mice, 
however, cyclin D1 could not be detected anymore neither in collaterals of the occluded nor the sham 
operated side via qRT-PCR. 
 
Figure 18: Assessment of cell cycle progression via qRT-PCR 
On the left side, vertical bar chart displaying cdc20, cyclin E and cyclin D1 mRNA in Egr1-/- mice 12h after 
femoral artery ligation. Representative agarose gels (right side) showing cdc20, cyclin E and cyclin D1 qRT-
PCR products of collateral arteries of WT and Egr1-/-mice 12h after ligation (upper 3 panel), lower panel display-
ing 18S showing that qRT-PCR ran efficiently. For cyclin D1 no signal was detected in Egr1-/- mice either on the 
occluded or the sham side, mean±SEM, *p<0.05 occ vs. sham. 
 
To test whether the loss of cyclin D1 expression was an overall phenomenon or whether this was only 
true for vessels, cyclin D1 expression was tested in other organs (brain and bone marrow) of Egr1 WT 
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and deficient mice (Figure 19). Interestingly, cyclin D1 was detectable in both groups in tissues with a 
higher mitose turnover such as brain and bone marrow. Still the data evidenced that in collateral ves-
sels of Egr1 deficient mice cyclin D1 expression dropped below the detection limit. 
 
Figure 19: Cyclin D1 expression in other organs of Egr1-/- mice 
Representative agarose gels displaying detectable cyclin D1 expression (upper panels) in bone marrow (BM) and 
brain of WT and Egr1 deficient mice. Lower panels displaying 18S to confirm that qRT-PCR ran efficiently. 
 
 
5.2 vSMC phenotype switch  
The data obtained from cell cycle regulators cdc20, cyclin E and D1 showed that there was a signifi-
cant difference in mitose progression between Egr1 deficient mice and wildtypes. Since cell cycle 
progression was likely to be impaired in the vasculature, expression of vSMC phenotype switch mark-
ers, such as SF-1 and αSM-actin, as well as proliferation marker ki67 were investigated in Egr1-/- and 
WT mice 12h after femoral artery ligation (Figure 20). On the occluded side of WT mice, SF-1 
(0.55fold occ vs. sham) as well as αSM-actin (0.46fold occ vs. sham) were found to be downregulated 
showing that already at 12h after ligation vSMCs start switching their phenotype, a prerequisite for 
vSMC proliferation. By contrast, on the occluded side of Egr1-/- mice, SF-1 was found upregulated 
(1.60fold occ vs. sham). Moreover, the previously described downregulation of αSM-actin was not 
detectable in Egr1 deficient mice. There was rather a tendency for upregulation detected in Egr1 defi-
cient collateral vessels which was however not significant. Since Egr1 deficiency apparently did inter-
fere with the phenotype switch, the range of proliferation was investigated in both groups. In WT 
mice, proliferation marker ki67 was found 1.65fold upregulated after ligation, showing a start in vas-
cular cell proliferation as early as 12h, whereas in Egr1-/- mice, no difference in occ vs. sham was de-
tected.  
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Figure 20: Asessment of vSMC phenotype switch and proliferation in collateral arteries of Egr1-/- and WT 
mice  
A: Vertical bar chart showing mRNA levels of SF-1 (on the left) and αSM-actin (on the right) 12h after femoral 
artery ligation in Egr1-/- and WT mice, mean±SEM, *p<0.001 occ vs. sham, #p<0.05 WT vs. Egr1-/-. 
B: Vertical bar chart displaying ki67 mRNA levels detected in growing collateral arteries12h after femoral artery 
ligation, mean ±SEM *p<0.05 occ vs. sham. 
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V. DISCUSSION 
 
In the present study, the function of Egr1 in terms of leukocyte recruitment and vascular cell prolifera-
tion in vivo was investigated in a murine hindlimb model of arteriogenesis. The data showed that col-
lateral artery growth is associated with increased expression of Egr1 on the mRNA and the protein 
level. Egr1 deficient and WT mice displayed increased expression levels of MCP-1, ICAM-1 and uPA 
on the site of arteriogenesis being important for leukocyte recruitment and extravasation. Whereas 
relative upregulation was similar to WT mice, the overall amounts of transcripts were significantly 
lower in Egr1 deficient mice. This indicates that in Egr1 deficient mice probably other members of the 
Egr family or other transcription factors compensate the function of EGR1, yet not efficiently. Under 
baseline conditions (sham side and unligated mice), reduced numbers of leukocytes were found in 
Egr1 decficient mice, whereas after femoral artery ligation, increased numbers of perivascular leuko-
cytes were detected. Cell cycle genes cyclin D1, cyclin E and cdc20 were not differentially expressed 
in WT mice. In Egr1 deficient mice cyclin E and cdc20 were found significantly upregulated, howev-
er, cyclin D1 was not detectable anymore in the vasculature, conferring EGR1 a unique role as tran-
scription factor regulating cyclin D1 expression during vascular remodeling. Moreover, the delay in 
proliferation could be explained by a disturbance in the critical vSMC phenotype switch in Egr1 defi-
cient mice as revealed by aberrant αSM-actin and SF-1 expression, which could not be counterbal-
anced in Egr1 deficient mice. 
1 THE MURINE ARTERIOGENESIS MODEL  
There is a large variety of experimental models to study the range of vascular remodeling. The differ-
ences within protocols are on the one hand due to different species used such as mice,126 rats,127 rab-
bits,128 dogs35 or pigs45 thereby applying different techinques to different anatomical settings and on 
the other hand due to different vascular supply areas (coronary,35 mesenteric,129 cerebrovascular130 or 
peripheral126 model) to choose from. The advancing knowledge and the recognition of the differences 
between angiogenesis and arteriogenesis, regarding gene expression for example, has shown that it is 
particularily interesting to study these processes selectively, independent from each other.  
1.1 Why using the murine peripheral femoral artery ligation model? 
Arteriogenesis differs decisively from angiogenesis in terms of initiation, regulation and purpose. The 
differences are mainly the initial trigger (FSS vs. ischemia), the fact that preexistent vessels develop 
and remodel instead of a new sprouting of vessels and the functional compensation of a stenosis, 
which is not possible with angiogenesis alone.39 Arteriogenesis is not ischemia related and can restore 
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adequate vessel conductance via collateral artery growth to transport oxygen-saturated blood to is-
chemic tissue.131 Angiogenesis and arteriogenesis, however, can occur at the same time in the same 
area. Since the role of Egr1 in arteriogenesis separately from angiogenesis had to be investigated, an 
animal model had to be chosen where arteriogenesis occurs solely and locally separated from ische-
mia-triggered angiogenesis. When focusing on peripheral arteriogenesis, there are basically two prin-
ciple models: the femoral artery excision model associated with ischemia and the femoral artery liga-
tion model.126 Due to the fast procedure, the femoral artery ligation model offers first an 
uncomplicated, second a very specific way of studying arteriogenesis and has a long tradition. John 
Hunter (see Introduction 1.3) conducted artery ligation experiments already in 1785. While hunting 
and observing deer in the royal Richmond Park, he became interested in the growth of antlers and 
investigated collateral artery growth in growing antlers after ligation of the external carotid artery.8 In 
a translational approach from his studies, he continued with femoral artery ligation in the dog before 
finally transferring the acquired operating technique to patients. In dogs, he wanted to gain evidence 
that the development of bypasses also occurs in a different species and in a different anatomical area.8 
A new rabbit femoral excision model associated with ischemia in the hindlimb was published in 1992 
to study angiogenesis.132 Schaper, who has been studying arteriogenesis by coronary artery ligation in 
the canine and porcine heart since the 1960s adapted and modified this model to generate a peripheral 
arteriogenesis model that separates angiogenenesis and arteriogenesis anatomically clear from each 
other.128 Femoral artery ligation offers the advantage to specifically study the molecular regulation of 
arteriogenesis in the m. adductor, semitendinosus and gracilis without interference from angiogenesis 
related factors.128, 131 By omitting a partial excision and performance of the nearly atraumatic ligature, 
it is excluded that vascular growth occurs due to wound healing or tissue necrosis.128 Ischemia does 
not occur within that area and ischemia related metabolites (e.g. ATP, ADP, AMP) did not differ with-
in the ligated and non-ligated side.131 An upregulation of HIF-1α could neither be detected.128 VEGF 
and its receptor Flt-1 were not found upregulated nor did external application of VEGF in high con-
centrations alter collateral conductance in a large range. The observed minor effects occurred rather 
via indirect activation of monocytes,133 expression of integrins and increased transmigration since 
monocytes do express Flt-1. The murine model, used in this study, permits to study angiogenesis in 
the thigh muscles separated from the adductor collaterals. Hence the ischemic area is clearly separated 
from the adductor area where arteriogenesis occurs and both processes can be studied separately with-
out interference from each other but within the same animal. Furthermore this model is suited as func-
tional model for exercise experiments.134 The murine femoral artery ligation model is more specific for 
the purpose of characterizing Egr1 function during arteriogenesis and superior to the femoral artery 
excision model.  
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1.2 Comparison to a coronary ligation model 
In principle, the process of arteriogenesis can occur and therefore be studied mechanistically in every 
organ or anatomical area of the body.35, 129, 130 The surgical procedure of peripheral arteriogenesis 
models is usually well tolerated with adequate postoperative analgesia making dropouts very rare. This 
is naturally not the case in a coronary model where the left anterior descending (LAD) coronary artery 
of the heart is ligated. This model is attended by a large variety in mortality (7-25%) and defect in 
cardiac function correlating with the variety in infarct size (8-65%, dependent on the study) and ana-
tomical placement of the suture.135  But apart from mortality there are also some structural differences, 
which also have to be considered. The hearts of different animals (pigs, dogs, guinea pigs, humans) 
differ decisively in terms of the formation of interconnecting arteriolar networks. The range of tissue 
damage after myocardial infarction as well as the induced collateral artery remodeling strongly relies 
on the structural morphology of the preexisting collateral network. In the guinea pig hardly any myo-
cardial infarction develops but maximal infarct size can be observed in the pig and rat heart. Whereas 
the pig depicts a quite similar three coronary vessel anatomy like humans, the dog shows typically two 
vessels. In the porcine heart, the collateral circulation is hardly developed whereas the canine epicardi-
al collateral circulation is well developed making it very sustainable even to multiple vessel occlu-
sions.136, So dependent on the studied animal the vascular anatomy is very variable. Moreover, angio-
genesis in the myocardium cannot be separated from arteriogenesis. Ischemia is induced at the time of 
ligation within the heart muscle and necrosis does occur. Since the aim of this study was to analyze the 
role of Egr1 for arteriogenesis strictly separate from angiogenesis, the use of a coronary model was not 
feasible. There are methods to gradually occlude a (coronary) vessel, which comes quite close to the 
typical clinical situation. Ameroidconstrictors, made of hygroscopic material, are placed around a cor-
onary artery and within 1-3 weeks the artery is occluded due to moisture expansion.137 However, the 
grade of occlusion is variable and therefore the grade of stenosis is hardly predictable. These constric-
tors are associated with a variable incidence of myocardial infarction and mortality rate therefore re-
ducing reliability even more. With further development of this method and the adaptation to other 
“clinical scenarios” such as chronic ischemic heart failure, it might serve as a very suitable model to 
simulate pathologies of the human heart.  
1.3 Peripheral arteriogenesis models in different species 
Aside from the murine model, other femoral artery ligation models in the peripheral circulation are 
well established. There are the rat,127, rabbit,128 and the porcine45 model. The rabbit femoral artery 
ligation model is the earliest and best characterized arteriogenesis model existing. Arteriogenesis 
models investigating the porcine circulation permit the transferal of achieved results into the human 
 DISCUSSION  
 
 52 
patient. The clinically known Bland-White-Garland syndrome is a rare congenital anomaly, where the 
left coronary artery branches from the pulmonary artery and blood flow is therefore directed from the 
right coronary artery via collateral vessels to the left coronary artery and from there into the pulmo-
nary artery following to pressure levels. Inspired from this condition, the working group around 
Schaper established a shunt model in the porcine hind limb, in which shear stress is always maintained 
in the collateral circulation,45 allowing to dissect FSS stimulated effects from other mediators of arte-
riogenesis. Research using the rat model is less frequent than using a murine model. Yet a simple ad-
vantage makes this model very attractive for basic research. A rat is evidently bigger than a mouse 
providing a larger quantity of tissue sample of collateral tissue isolated from the adductor muscle. 
Moreover, more advanced surgical (i.e. the transferal of the arterio-venous shunt arteriogenesis model 
into the rat) and imaging methods can be applied.134 This widens the range of study designs to choose 
from and eases gene expression studies. However, knockout and transgenic models are barely availa-
ble until now but might be on hand in the future.  
Mice represent good research animals due to their short generation time and large variety of genetical-
ly engineered strains, such as transgenic or knockout models, as used in this study. Here the negative 
influences of deficiency can be studied. The control mice on a C57Bl/6 background, shows the best 
performance in collateralization when compared to other standard control strains such as the sv129S or 
the Balb/C mouse.138, 139 The latter exhibited the lowest collateral flow immediately after femoral ar-
tery occlusion (C57Bl/6 has been shown to have a 7 fold higher acute collateral flow) resulting in se-
vere ischemia of the lower extremity and a slower perfusion recovery. On day 21, when C57Bl/6 mice 
have a fully developed collateral circulation (100% compared to sham), the Balb/C strain exhibits only 
50% of perfusion recovery.138 Therefore a reduction in arteriogenesis due to application of certain 
inhibitor substances or gene loss of function is studied best in the C57Bl/6 background, whereas thera-
peutically designed studies should be studied in Balb/C or sv129S. Due to the higher operating ex-
penses, large animal experiments are reserved for preclinical experiments whereas small animal mod-
els dominate basic research. 
1.4 The influence of gender 
An additional word might be added to the role of gender in arteriogenesis. In animal studies mostly 
male animals are used since the range of influence of the female hormone cycle (i.e. positive effects of 
estrogen) is barely evaluated in this model. A publication of 2003 found no differences in angiogenesis 
or arteriogenesis between male and female rabbits after femoral artery excision140, however oophorec-
tomized females displayed a defect in recovery most likely due to the loss of estrogen. A more recent 
publication studying mice also after femoral artery excision started to shed light on basic mechanisms 
and came to the conclusion that females performed less well in terms of functional perfusion recovery 
and angiogenesis in vivo as well as vascular cell proliferation and capillary sprouting in vitro. 141 This 
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relates quite well to clinical data showing a higher prevalence of PAD in women, which however 
tended to be older suggesting once more a positive influence of estrogen.142 It brings some difficulties 
to evaluate a larger group (>5) of female mice since housing would have to be in one cage to ensure 
timely equalized hormone cycles in all animals or one is forced to use oophorectomized animals, 
which is a severe intervention without a true correlation to the desired study aims. But the clinical 
treatment will focus more and more on personalized medicine, which requires a profound knowledge 
on gender differences in health and disease and will therefore challenge researchers to acquire more 
knowledge especially in this field. 
2 EGR1 AND ARTERIOGENESIS  
Arteriogenesis, the growth of pre-existing collateral arteries into functional arteries relies on the pro-
liferation of ECs and vSMCs143, 144 and is strongly dependent on perivascular accumulation of leuko-
cytes, in particular monocytes, supplying the growing vessel with growth factors and cytokines.55, 56, 145 
Egr1 has been shown to participate in these processes at least in vitro and therefore renders the periph-
eral arteriogenesis a powerful tool to analyze Egr1 function in terms of vascular cell proliferation and 
leukocyte recruitment in vivo.  
There is an increasing body of evidence that after femoral artery occlusion, flow alterations in small 
preexisting collateral arteries lead to increased shear stress, which subsequently activates the collateral 
endothelium and triggers the whole process.45, 68, 130 It appears that elevated fluid shear stress is the 
universal and prime initial stimulus for arteriogenesis not only in muscle tissue51 but also in brain130 or 
heart. It is not clear, however, how this elevated shear is sensed by the EC, coded to information and 
transmitted to vSMCs for example. PECAM-1 has been proposed to form part in such a shear sensing 
mechanotransductory complex in ECs in vitro.48 During arteriogenesis PECAM-1 deficient mice ex-
hibited a different EC morphology, i.e. smaller size, resulting in a delay in perfusion recovery.146 But 
so far, the role as a mechanosensing receptor could not be entirely proven in vivo. Similarly, various in 
vitro studies found Egr1 rapidly expressed in ECs after exposure to shear stress.79 The acquired results 
indicate that this might also be the case in vivo. In own preliminary intra vital microscopy experiments 
(n=5), where the femoral artery of C57Bl/6 mice was ligated while focusing on one of the superficial 
collateral arteries, the vessel showed immediate vasodilatation after ligation, which started from the 
entry point close to the a. profunda femoris and within 5min the whole vessel vasodilated and re-
mained this way until the end of the observation period which was 30min after ligation (data not 
shown). Moreover, velocity measured with fluorescent micro beads increased dramatically. Baseline 
velocities were 8824.72±583.59µm/s (a. profunda) and 2288.98±205.56µm/s (collateral artery). Di-
rectly after ligation the velocity did not increase significantly in the a. profunda femoris 
(9109.05±940.75µm/s, p=0.75) but velocity in the collateral vessel nearly adapted the speed of the 
larger vessel (7248.15±542.06µm/s, p<0.00005). High shear stress induced vasodilatation in rat mes-
 DISCUSSION  
 
 54 
enteric resistance arteries has been shown to be nitrous oxide (NO) and reactive oxygen species (ROS) 
dependent.147 Despite its well-described anti-inflammatory and anti-proliferative active profile, there 
are studies that notice in NO a contributor to arterial outward remodeling.148 Moreover, Egr1 belongs 
to the NO early responding genes.149, How NO affects collateral artery growth still remains under dis-
cussion. It has been shown, that constantly increased amounts of oxidizing agents activate various 
signaling pathways aiming at the promoter of “redox sensitive” genes. One of these genes is Egr1. 
Hydrogen peroxide at non-toxic doses has been shown to rapidly induce Egr1 mRNA and protein ex-
pression.150 Moreover, previous studies described that the DNA binding capacity of EGR1 is redox 
regulated in vitro. Cystein residues within the DNA-binding domain of the protein are oxidized and 
severely reduce the DNA binding capacity of EGR1 whereas under reducing conditions DNA binding 
is enhanced 151. Under non-toxic ROS levels, the EGR1 binding ability is rescued by activation of an 
apurinic/apyrimidinic endonuclease 1 (APE-1).80, 151 APE-1 is a DNA repair enzyme with nuclear re-
dox activity.152 In various cell types, ROS induce nuclear translocation of APE1, which in turn induces 
DNA binding of transcriptional regulators. APE-1 restores EGR1 DNA binding by direct protein – to 
protein interactions and even enhances its transcriptional activity in vitro and in vivo. Moreover, evi-
dence for a positive auto regulatory loop between APE-1 and Egr1 exists,80 mutually maintaining their 
transcriptional activity under non-toxic redox conditions. To prevent a never-ending activation be-
tween APE-1 and EGR1,85 86, 153 both factors are capable to downregulate their own expression via a 
negative feed back mechanism. Our data gathered from WT mice evidenced that after femoral artery 
ligation, when FSS and very likely high ROS levels occur, Egr1 is upregulated in growing collateral 
arteries in a time dependent manner. On the mRNA level, Egr1 was found to be upregulated as early 
as 12h after femoral artery ligation, which persisted until 48h after ligation. Accordingly, the protein 
levels of EGR1 were found upregulated on the occluded side starting at 24h after ligation and were 
also detectable at 36h and 48h. Proliferation and adaptation of collateral vessels to the altered FSS 
start rapidly. And it is the timely decrease in FSS inversely related to the enlargement of the collateral 
diameter that eventually stops the remodeling process, as seen in the previously discussed shunt mod-
el.45 This makes a shear stress dependent upregulation of EGR1 very likely, since at day 3, when leu-
kocyte infiltration and proliferation peak, EGR1 was not found differentially expressed anymore. Egr1 
deficient mice exhibited a strong delay in perfusion recovery over 21 days as shown by Laser Doppler 
analyses. These results are in line with the previously reported findings of impaired collateral artery 
growth in Egr1-/- mice after whole femoral artery excision.96 Therein it has been shown that the mor-
phology of large and small vessels as well as the number of capillaries was similar in WT and defi-
cient mice. However, they documented that Egr1 deficient mice showed fewer number of arterioles in 
the adductor muscles. Furthermore, Egr1 deficient mice showed severe gangrene whereas in the pre-
sent study this was not observed. This is very likely due to the excision of the femoral artery, which 
already induces ischemia in the adductor muscle leading to a more severe ischemic damage in the calf 
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muscle.96 Apart from this study it has been shown, that adenoviral gene transfer of Egr1 accelerates 
perfusion recovery. 97 However, the authors focused mainly on the mechanistic insights into angiogen-
esis of the calf muscle and tallying with previously reported findings, Egr1 overexpression greatly 
enhances angiogenesis.154. In this study the focus lied on the role of Egr1 during arteriogenesis, a sub-
ject, which has not been covered by the previous reports.  
3 LEUKOCYTE RECRUITMENT 
Leukocyte (especially monocyte) recruitment into the perivascular space of growing collateral arteries 
is a critical mechanism during arteriogenesis.53, 145 Monocytes derive from the bone marrow and pass 
through several developmental stages (hemocytoblast, common myeloid progenitor, myeloblast, mon-
oblast, promonocyte) until they transmigrate and mature to macrophages in the tissue. The maturation 
process is controlled by growth factors. Differentiation from pluripotent stem cells to myeloid progeni-
tor cells is mediated by interleukin (IL-3). Further differentiation to monocyte/macrophage lineage is 
mediated by macrophage colony-stimulating factor (M-CSF) and granulocyte macrophage colony-
stimulating factor (GM-CSF). Thus, the intermittent or continuous infusion of GM-CSF increased 
arteriogenesis in a pig model of femoral artery ligation.155 It has been described that monocytes and 
neutrophils express EGR1,156, 157 and it has been shown that EGR1 is crucial for development of hema-
topoietic stem cells along the macrophage lineage.158 
Under baseline conditions in unligated animals, Egr1 deficient mice evidenced higher cell counts of 
granulocytes and monocytes in the peripheral blood compared to WT mice. Accordingly, fewer leuko-
cytes in particular macrophages, T- and B-lymphocytes could be detected in the whole digested adduc-
tor muscle of Egr1-/- mice in comparison to WT mice. After femoral artery ligation, however, the 
number of perivascular-accumulated macrophages increased dramatically in Egr1-/-. On the sham side 
of the latter, there were still reduced numbers of macrophages matching nicely with the reduced base-
line cell counts within the muscle. It appears that Egr1 is crucial for the differentiation of a variety of 
cells along the macrophage lineage, not only for WT- myoblasts but also for leukemia cells or hema-
topoietic stem cells. 98, 158 Moreover, it has been shown that Egr1 also participates in B-cell develop-
ment159 and T-cell differentiation.160 It could therefore be argued that the increased baseline blood 
levels of leukocytes and monocytes in Egr1-/- mice reflect an impairment of cell maturation, which 
leads to an overproduction of cells by the bone marrow. This is an effect, which can be frequently 
observed in myeloid leukemias. Moreover, it has been reported for different knockout models associ-
ated with a defect in leukocyte recruitment that they evidence an increase of leukocyte cell counts in 
the blood.161 The reduced cell number found in the whole adductor muscle and on the sham side of 
Egr1-/- mice furthermore strongly suggests an impairment of cell recruitment under baseline condi-
tions. Stimulus directed migration, however, appeared to be still working, since we could detect mac-
rophages in the perivascular area of growing collaterals. We even found a higher number than in WT 
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mice. It seems that after the induction of a strong stimulus, the degree of leukocyte transmigration 
occurs mediator dependent and in accordance with the respective circulatory level of such cells ac-
counting for the elevated number of perivascular cells in Egr1 deficient mice after femoral artery liga-
tion. The constitutive expression of EGR1 in monocytes and neutrophils most likely reflects the ability 
to quickly respond to inflammatory stimuli.156 However, it was reported that monocytes isolated from 
the blood and from various tissues of Egr1-/- mice showed no defect in activation upon stimulation.162 
EGR1 is crucially involved in the transcriptional control of many genes involved in monocytic activa-
tion and differentiation163 so that it seems nearly unlikely that an Egr1 loss of function should have no 
effect on monocyte function. This might also be due to a compensatory effect of EGR2, which plays a 
major role for leukocyte function, especially during T-cell112 and monocyte activation98 and might 
compensate for Egr1 gene loss of function. Nevertheless, activation of leukocytes seemed to be work-
ing, whereas it was the baseline function and recruitment that evidenced defects. It might therefore be 
that accordingly to the constitutive expression of EGR1 in monocytes, EGR1 is especially responsible 
for the continuous recruitment whereas in acute inflammatory reactions, where a fast response is nec-
essary, many other TFs as well as other Egr family members are capable of recruiting these cells into 
the site of inflammation.  
Recruitment of leukocytes into the perivascular space cannot be undertaken without the help of cyto-
kines, adhesion molecules and proteinases. Therefore, the mRNA levels of distinct effector genes in-
volved in the recruitment of leukocytes were analyzed (MCP-1, ICAM-1 and uPA) that might repre-
sent EGR1 dependent downstream genes, due to their promoter characteristics102 or expression 
profiles.103 Reduced mRNA levels of all three transcripts on the sham and the occluded side of Egr1-/- 
mice in comparison to WT mice were found. The lower expression under sham conditions in Egr1 
deficient mice further supports the data from the whole tissue digestion experiments and the sham side 
of ligated animals where reduced numbers of leukocytic cells were detected in the tissue. Interestingly, 
the upregulation of MCP-1, ICAM-1 and uPA in response to femoral artery ligation was not impaired 
since their relative expression (occ vs. sham) was similar in Egr1-/- and WT mice also at a later 
timepoint (24h after ligation). It still appears, that all three transcripts might be accounting for the 
higher number of perivascular leukocytes. Here again the role of other members of the Egr family in 
terms of similar function or compensatory mechanisms has to be considered since all of the members 
are capable of binding to EBS but the data on these members are only few. It has, however, previously 
been described that EGR3 and -4 are able to upregulate ICAM-1 in vitro by interacting with NFκB 
p65.164 This might also be the case in this model in vivo. Moreover, targeted disruption of the MCP-1 
receptor, CCR-2, almost abolishes collateral artery growth due to impaired monocyte recruitment.165 
Hence, MCP-1 seems to be the superior cytokine in mediating arteriogenesis.53 It is therefore more 
than likely that other transcription factors or also members of the Egr family might be able to upregu-
late MCP-1 without the presence and proper function of EGR1. The LDI perfusion data revealed a 
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significant delay in perfusion recovery but not a near abolishment of collateral artery growth meaning 
that MCP-1 was exerting its functions in Egr1 deficient mice.  
4 EXPRESSION OF EGR FAMILY MEMBERS – EVIDENCE FOR COMPENSATION 
Egr1 forms a family of Egr TFs together with three other members, Egr2,107 Egr3166 and Egr4.167 All of 
them show the characteristic three tandem repeat zinc finger structure and differences are mainly out-
side the DNA binding area.107, 108 Accordingly, all Egr-TFs bind to the EBS of Egr target genes. In WT 
mice, a downregulation of Egr2 and Egr3 at 12h and 24h after femoral artery occlusion was detected 
compared to the sham side. These data are in line with findings in T-cells showing that Egr2 and 3 
were regulated contrariwise to Egr1.112 In Egr1 deficient mice, however, Egr2 and 3 were upregulated 
and the expression levels of Egr4, which were already upregulated in growing collaterals of WT ani-
mals, were further increased in Egr1-/- mice. Egr1 deficient mice are viable and display a quite mild 
phenotype considering all the essential processes Egr1 is involved in. These mice do not show any 
obvious defects in cellular differentiation.121 Nevertheless, female knockout mice are sterile due to the 
loss of Egr1 mediated mRNA transcription of luteinizing hormone (LH) in the gonadotropin-releasing 
hormone (GnRH)-LH axis.120 Egr2 deficient mice however are embryonically lethal109 whereas Egr3-/- 
are viable but with a striking phenotype.168 So it seems that Egr1 loss of function can be tolerated quite 
well most likely due to compensation in between the family, as already proven for Egr4.119 It has been 
shown in Egr1 deficient mice that Egr2 is capable to execute the function of Egr1 in B-lymphocyte 
development.159 Moreover, Egr2 has been described to be responsible for monocytic activation on an 
equal level with Egr1, though in an in vitro setting.98 For EGR3 and especially for EGR2 functions this 
seems to be not the case. An important issue, if one discusses the idea of compensatory mechanisms 
within the Egr family, is the internal activation and transcription control between their members. 
When EGR1 binds to its own promoter this does not result in a further upregulation as binding of 
EGR1 to an EBS normally does. It results in a downregulation of Egr1 in order to control enduring 
activation (negative feedback mechanism86 of Egr1). What remains unclear is how this downregulation 
is controlled or mechanistically resolved and - if this were a special characteristic feature of the EBS 
of Egr promoters – what functional element might be the reason for that. Moreover, if we look at the 
expression of Egr2 and Egr3 in WT mice after femoral artery ligation, might it not be feasible to hy-
pothesize that EGR1 after upregulation also binds to the promoters of Egr2 and 3 and downregulate 
their transcription in the same way? Up to now there is no data proving this theory, and in vitro studies 
planned to answer this question will be quite extensive. But it seems logical that EGR1 binding to the 
Egr-family’s own EBS leads to a downregulation in order to prevent an overshoot expression. We 
know that Egr family members are activated by similar stimuli.115 Therefore a typical activating stimu-
lus (such as shear stress) should actually result in the upregulation of more than one Egr family mem-
ber at and over the same time, however this is rarely the case.115 Therefore there has to be a control 
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mechanism involved preventing needless redundancy of gene activation, which is also important to 
protect the surrounding tissue of simultaneous gene activation at the same time point which might 
result in an Egr-related „expression storm“. So looking back at the data, the downregulation of Egr2/3 
is quite well explained with this hypothesis. Another interesting player in this inter-family control 
scheme is NAB-2. As already mentioned NAB-2 is induced by EGR1 in a time-staggered way. Inter-
estingly, a recent study could show that not only EGR1 but also EGR2 and EGR3 are capable of bind-
ing on the promoter of NAB-2, thereby establishing a triple negative feedback.169 Therefore, if Egr1 is 
activated by an upstream signaling cascade (e.g. MEK/ERK) and induces NAB-2, this repressor will 
eventually bind to Egr2 and Egr3 since their promoters also exhibit a NAB-2 binding site. This will 
result in a downregulation by NAB-2 whereas Egr1 levels will remain constantly upregulated until the 
upstream activation signal is silenced. The control of upstream signaling cascades on distinct members 
of the family under similar stimuli conditions has already been described for Egr1 and Egr3.115 It was 
shown in the very same study that upregulation of Egr3 was longer than that of Egr1 due to different 
upstream signaling cascades but during the same stimulus driven conditions. So when the upstream 
activation signal shuts down, this results in an important stop signal. NAB-2, induced by one still acti-
vated Egr member, will eventually stop the other members, presenting a powerful and fast expression 
control mechanism. However if the upstream signal does not shut down, for example due to an aber-
rant activation in cancer, the negative feedback loop cannot work and the more upstream cascades are 
deregulated the higher the probability to activate all Egr resulting in ongoing, uncontrolled mitosis.  
For Egr4, the regulation might be slightly different, since Egr4 does not exhibit a NAB-2 binding site. 
Moderate activation of Egr4 was already seen in WT mice, which then was further pronounced in 
Egr1 deficient mice. Egr4 plays a major role in male fertility116, 117 and it is Egr4 that protects male 
Egr1 deficient mice from infertility.119 Therefore, not surprisingly, Egr4 deficient mice are infertile.118 
As stated before, all Egr family members bind to the EBS, however, EGR4 has been shown to display 
a threefold lower DNA affinity compared to EGR1 to -3.170 Once again one might argue that Egr1 is 
missing at the promoter of Egr4 thereby stopping the inhibition. However, it has been described that 
EGR4 acts as a transcriptional repressor via binding to its own promoter.171 In the same in vitro study 
it was shown that EGR1 did not negatively alter Egr4 promoter activity but the binding site on the 
Egr4 promoter is not described as typical EBS, rather as a large section of GC sequences. So it re-
mains unclear how much of the EGR1 protein can actually bind to Egr4. Nevertheless, it seems that 
Egr4, which overtakes important functions in Egr1 deficient mice, is „missing“ at the GC rich binding 
site of its own promoter thereby stopping the very own transcriptional repression leading to high levels 
of EGR4 protein in Egr1 deficient mice. These data together with our data strongly indicate that other 
members of the Egr family are capable to overtake the tasks of Egr1 and compensate its loss of func-
tion in terms of monocyte recruitment and activation. However, further studies are necessary to con-
firm this and to assign individual functions to distinct members of the Egr family in order to unravel 
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which signal transduction cascade targets which promoter, and which member can activate which 
downstream gene as an alternative to Egr1 activity.  
5 CELL CYCLE PROGRESSION AND PROLIFERATION  
5.1 Expression of cyclins in growing collaterals 
Cyclin D1 and cyclin E promote cell cycle progression from G1 to S-phase.95 Cyclin D1 binds to cy-
clin-dependent kinases CDK 4 and CDK6 forming active holoenzymes that can phosphorylate the 
retinoblastoma protein (Rb). Upon phosphorylation, Rb releases the transcription factor E2F, which in 
turn activates genes essential for G1–S transition and S-phase.172 Cyclin D1 can also control cellular 
functions in a CDK-independent way through direct interaction with transcriptional regulators and 
nuclear receptors.173 Cyclin D1 differs from other cyclins due to the fact that it is induced by mitogens 
such as growth factors and integrins as a delayed early gene in G1 phase.174 EGR1 influences on dif-
ferent key regulators of proliferation such as cdc20, cyclin D1/E, Cdk4 and proliferating cell nuclear 
antigen (PCNA) have been described for in vitro settings.175 The relationship of Egr1 and cyclin D1 is 
quite frequently analyzed in the context of tumor progression. In prostate cancer cells, for example, it 
has been shown that the MEK/ERK1/2 pathway mediated upregulation of Egr1 led to an activation of 
cyclin D1.175 In the current study the analyses of cell cycle regulators revealed no differential expres-
sion pattern of cdc20, cyclin E and D1 in WT mice at the timepoint 12h after ligation. Apparently the 
amount of protein synthesized from these genes was present in sufficient amounts for baseline (sham 
side) cell cycle progression as well as after femoral artery ligation. Egr1-/- mice expressed lesser 
amounts of cyclin E and cdc20 under sham conditions. However, after femoral artery ligation, these 
genes evidenced a differential expression pattern and as such were strongly upregulated. Cyclin D1, on 
the other hand was below the detection limit in collateral arteries in Egr1 deficient mice either on the 
occluded or the sham operated side. In brain and bone marrow tissue, however, cyclin D1 was found 
to be expressed in equal amounts in WT and Egr1-/- mice. The data tally with findings showing that 
Egr1 silencing in primary rat carotid vascular smooth muscle cells employing Egr1 decoy oligodeox-
ynucleotides176 resulted in significantly reduced expression levels of cyclin D1. The close relationship 
between Egr1 and cell cycle regulators and the range of their expression seems to be tissue dependent 
as the different expression patterns seen in collateral artery tissue compared to brain or bone marrow 
tissue indicate. This seems also be true for hepatic tissue. During hepatocellular mitosis it has been 
shown that Egr1 deficient mice failed to progress from metaphase to anaphase, which was due to a 
lack of cdc20 induction a key regulator promoting anaphase progression. However, here the authors 
were able to detect cyclin D1 and E in Egr1 deficient mice.95 It is again most likely that the signaling 
cascades involved in the pathological and physiological processes that govern mitosis and cell cycle 
progression also rule over the associated Egr1 downstream genes. Which type of cell cycle regulator is 
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involved depends apparently on the tissue, the stimulus and the participating genes. As for arteriogen-
esis, cyclin E and cdc20 can be upregulated when cyclin D1 is missing, but nevertheless adequate cell 
cycle progression and proliferation requires cyclin D1 in growing collateral arteries which in turn re-
quires activation of Egr1, an effect which could not be compensated efficiently by other transcription 
factors.  
5.2 vSMC phenotype switch: role of SF-1 and αSM-actin 
Vascular smooth muscle cell differentiation from the contractile to the synthetic type is a critical pro-
cess during arteriogenesis and a prerequisite for proliferation. During this change in phenotype, typical 
cytoskeletal proteins such as desmin, calponin and vinculin are downregulated, the abundant actin 
filaments disappear143 and a prominent rough endoplasmatic reticulum can be observed.51 Therefore, 
vSMC proliferation and phenotype switch in arteriogenesis are strongly dependent on downregulation 
of αSM-actin70, 71 and the transcriptional repressor SF-1.69 To investigate whether αSM-actin is down-
regulated in wildtype and also in Egr1 deficient mice and whether Egr1 might regulate SF-1 downreg-
ulation not only in vitro106 but also in vivo accounting for the synthetic type of SMCs, αSM-actin and 
SF-1 expression was analyzed. And indeed, SF-1 and αSM-actin were found downregulated in grow-
ing collateral arteries of WT animals at 12h after femoral artery ligation but not in Egr1 deficient mice. 
Moreover, SF-1 was significantly upregulated in Egr1 deficient mice on the occluded side when com-
pared to the sham side. These data strongly indicate that the switch from the contractile to the synthet-
ic phenotype is at least attenuated in Egr1 deficient mice. This is an Egr1 effect that again cannot be 
substituted for by other transcription factors to promote vSMC proliferation. Actin is a 42kDa cyto-
skeletal protein found in microfilaments and thin filaments, which are part of the contractile apparatus. 
Hence, actin is important for maintenance of cell shape, contraction, cell motility, organelle movement 
and cell signaling. There are three isoforms, alpha, beta and gamma wherein the alpha actins are found 
in muscle tissue and in the contractile apparatus. Beta and gamma forms mostly mediate internal cell 
motility.177 Another quite well known member of cytoskeletal proteins is Ras homologue gene family 
(Rho) member A (RhoA). It is a small guanosine triphosphatase (GTPase) participating together with 
its effector Rho-associated coiled-coil containing protein kinase (ROCK) in stress fiber formation and 
cell cycle progression.177, 178 RhoA is upregulated in growing collaterals and long term inhibition of 
ROCK via Fasudil strongly inhibits arteriogenesis.34 If one takes a closer look at the upstream signal-
ing cascades that target the Egr1 promoter an interesting relationship between αSM-actin and Egr1 
becomes apparent.76 As already mentioned, MEK/ERK1/2 lies upstream of Egr1 and is easily activat-
ed in response to alterations in FSS.46 Activated ERK translocates into the nucleus and promotes bind-
ing of Ets-family transcription factor Elk-1 to the DNA. On the promoter of Egr1, in close proximity 
to the SREs, binding sites for Elk-1 (GGAA/T) are localized indicating reciprocal activation. SRF is 
classically dependent on binding of ternary complex factors (TCFs) Elk-1, Sap-1 and Sap-2, to acti-
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vate transcription.179 And in fact, Elk-1 and SRF form a ternary complex and synced activate transcrip-
tion180 combining the MEK/ERK pathway with SRF associated gene regulation. Myocardin, a SRF 
cofactor is specifically expressed in cardiac and smooth muscle cells. It powerfully stimulates SRF-
dependent transcription in a variety of cell types and is critical for vSMC differentiation in vivo.181 
Myocardin-related transcription factor (MRTF) A (also known as MAL/MKL1) and –B (MKL2) have 
been described to act similar to Myocardin.182 MRTFs are expressed more widely and are differential-
ly regulated by subcellular localization. In a resting state, MRTF-A remains in the cytoplasm when 
bound to monomeric globular actin (G-actin) via its RPEL motif.183 Rho has been described to pro-
mote translocation of MRTFs into the nucleus, an important step in stimulating vSMC-specific gene 
expression.184 Upon activation of the Rho/ROCK cascade, G-actin levels drop and MRTF-A, dissoci-
ated from G-actin, translocates into the nucleus to enhance SRF activity.185 The low levels of G-actin, 
responsible for MRTF-A translocation and SRF mediated transcription, are due to LIM-kinase-1 
(LIMK-1) mediated cofilin inactivation. LIMK-1 a serine/threonine kinase found to lie downstream of 
Rho, inactivates cofilin via phosphorylation both in vitro and in vivo.186 Cofilin is known to be a potent 
regulator of actin filament dynamics and is able to bind and depolymerize actin. Cofilin was found 
upregulated EC and vSMCs during arteriogenesis.45, 70 Rho activates LIMK-1, which inactivates cofil-
in thus generating low G-actin levels. As stated before, SRF activation is highly supported by either 
Elk-1 or myocardin/MRTFs. So it seems that it is not SRF but rather the co-enhancer families Ets and 
MRTFs that recruit and compete for SRF to promote transcription of their respective downstream 
genes, i.e. Egr1 or cytoskeletal proteins. This means, that during arteriogenesis, Egr1 is upregulated 
likely via MEK/ERK1/2 and SRF binding on the promoter. SRF then is missing at the promoter of 
cytoskeletal genes such as αSM-actin eventually resulting in a downregulation, which was seen in WT 
but not in Egr1 deficient mice. Using electron microscopy in a rat model of balloon-injured arteries, it 
has recently been shown that Egr1 decoy oligodeoxynucleotides inhibit the switch from the contractile 
to the synthetic phenotype of vSMCs.176 Failure to switch to the synthetic phenotype will inhibit pro-
liferation of vSMCs, which also might explain the delay in collateral artery growth as seen in the LDI 
perfusion measurements of Egr1 deficient mice. 
Ki67 is expressed in all cell phases except in Go - phase, can be found in all proliferating cells and is 
therefore a well-known proliferation marker. At 24h after ligation ki67 was found upregulated in 
growing collaterals of WT mice, whereas in Egr1-/- mice, no difference was detected. This result goes 
inline with the results of Vazquez-Pardon et al187 who performed ki67 staining on iliac artery tissue 
samples and found that Egr1 silencing prevented nicotine-enhanced neointimal formation in the rat 
balloon injury model. Moreover, previous studies in vitro with human aortic smooth muscle cells 
(HASMC) after transfection with small interfering RNA targeting EGR1105 and in vivo with Egr1 defi-
cient mice showing impaired recovery from partial hepatectomy95 support the findings that Egr1 is an 
important factor for cell cycle progression and proliferation and decisively regulates phenotype switch 
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during arteriogenesis, a function that can not be entirely counterbalanced by other transcription fac-
tors.  
In summary the data show that Egr1 regulates the recruitment of leukocytes especially monocytes into 
the perivascular space. However, this can also be achieved by other TFs such as the other Egr-family 
members (Egr2, Egr3 and Egr4). Cyclin D1 controlled proliferation and mitotic progression in the 
vascular bed in vivo is dependent on Egr1 since loss of function could not be compensated efficiently 
by another transcription factor. Egr1 controls the critical phenotype switch of vSMCs during arterio-
genesis, a prerequisite for proliferation. Therefore, vascular remodeling in arteriogenesis directly relies 
on EGR1 function controlling more than one aspect in this multifaceted process. Therefore, EGR1 
might be an important intercept point for therapeutic applications in patients in the future. 
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VI. THE PROSPECTS OF CLINICAL ARTERIOGENESIS THERAPY 
 
Over the past years new information has been gathered to unravel how the process of arteriogenesis 
works and several factors such as GM-CSF or FGF have been identified that might work as treatment 
option for patients. GM-CSF has been clinically tested in the coronary188 as well as in the peripheral189 
circulation, however, these trials showed no or only little success and in some cases were accompanied 
with severe side effects that led to premature termination of these trials. FGFs have also been quite 
extensively studied in clinical settings190 via single or multiple infusions in the coronary circulation 
and even using an adenoviral gene transfer.191 Common problems with most of the trials is that very 
few are conducted under true double blind placebo-controlled conditions, the fact that different prima-
ry end-points are set and methods for the evaluation of collateral growth and/or angiogenesis are used 
inconsistently. Seiler et al established new quantitative methods for the assessment of the coronary 
collateral circulation in humans during routine PTCA.192 Hence a low pressurederived collateral flow 
index (CFIp) (measured using a pressure guidewire) has been shown in a 10-year follow-up study to 
be an independent prognostic factor for cardiovascular mortality.193 Moreover, this study evidenced 
that a collateral coronary circulation is life saving. In a different approach the arteriogenesis network 
trial 2, a prospective, controlled, proof-of-concept study,194 analyzed the effects of external counter 
pulsation (ECP) collateral flow. ECP describes a noninvasive technique employing three pairs of 
pneumatic cuffs wrapped around the lower extremities. ECG triggered cuff inflation at the onset of the 
diastole and deflation at the beginning of the systole augments diastolic blood flow volume and blood 
pressure and decreases systolic pressure.195 ECP was able to improve fractional flow reserve and 
CFIp.196 Pushing collateral artery growth in patients using the initial stimulus has been proven to be 
effective. The identification of pro-arteriogenesic factors and their translation into clinical practice 
might as well further enhance the mechanical support given by ECP. However, the quite disappointing 
results of highly anticipated clinical studies using single molecules, which have been proven to be very 
beneficial in preclinical trials, showed that controlling a very complex mechanism such as arteriogene-
sis with one single molecule does not seem feasible.189 The true complexity of vascular remodeling is 
the reason why the application of a single growth factor cannot improve the patients’ outcome in a 
clinical setting. The present work focused on Egr1 and its role in promoting arteriogenesis. Egr1 is 
important for smooth muscle cell proliferation in arteriogenesis and when Egr1 is found in the biopsies 
taken from aneurysms and aortic plaques of patients, it would not be prudent to rate this as a poor 
prognosis or pathogenesis factor just because of its presence.197 Egr1 is important for the “daily-
routine- mitosis” and it appears that in most cases Egr1, as well as other TFs, is reigned by transcrip-
tion cascades that mediate its action and control its power.76 Although Egr1 has become a very well 
known player in tumor biology, it has never been understood whether it is friend or foe. It rather de-
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pends on the specimen that was investigated whether it was in vivo or in vitro and what kind of signal-
ing cascades have been studied in this context.76 It seems obvious that stimulation of Egr1 promoted 
growth in patients simply by entirely overexpressing Egr1 is neither the path to resolve the problem 
nor is it very wise due to the side effects that might occur such as uncontrolled proliferation leading 
inevitably to cancer. Looking ahead to the future of iatrogenic arteriogenesis therapy in patients, can 
Egr1 therefore be a drug target at all? The answer might be found in the identification of upstream 
signaling cascades that play a role in arteriogenesis and are specifically capable of switching on and 
switching off genes thereby controlling the process. The coordination of the many different cell types 
participating in vascular remodeling requires a broad range of signal transduction cascades activated 
simultaneously in different “vascular compartments“. As an example for the different signal transduc-
tion cascades, the MEK/ERK1/2 pathway has been shown to participate in arteriogenesis. ERK 1/2 is 
activated in response to increased FSS34 and lies upstream of Egr1.76 In vitro, MEK inhibition abol-
ished the typical desmin downregulation during vSMC transformation and led to cell cycle arrest.198 
So in this case MEK/ERK1/2 was the “on-switch” for the vSMC phenotype switch. The identification 
of signaling cascades lying upstream of Egr1 and eventually leading to the appropriate translation of 
the desired protein during collateralization will be part of future studies. A more recent study showed 
that by applying the commonly prescribed angiotensin-converting enzyme inhibitor Ramipril in pa-
tients suffering from intermittent claudication led to an alteration in geneexpression of many different 
players in arteriogenesis and simultaneously improved the patients’ walking time.199 Here we observe 
that by stimulating a multitude of factors regulating arteriogenesis at the same time can have an effect 
on the clinical outcome. These results are promising, however the future will tell if this treatment can 
be applied to daily clinical routine. To clinically employ arteriogenesis, we still need to analyze the 
different interplay between signaling pathways that modulate the distinct “levels” of communication 
between cells orchestrating collateral artery growth. This knowledge will provide us with the basis to 
develop new, modern and safe pharmaceuticals to induce arteriogenesis in patients and maybe even to 
prevent the incidence of arterial occlusive disease. 
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VII. SUMMARY 
 
The number of patients suffering from obstructive arterial disease is still increasing. Stimulation of a 
patient’s collateralization (arteriogenesis), though an auspicious therapeutic approach, is still not part 
of current therapy regimes. Further studies on the molecular level are needed to understand the genetic 
regulation in this process. The transcription factor early growth response 1 (Egr1) was shown to partic-
ipate in leukocyte recruitment and cell proliferation in vitro. This work contributes to the acquisition 
of new insights into its mode of action in vivo.  
Using a model of peripheral arteriogenesis, Egr1 was found significantly upregulated in growing col-
laterals of wild-type mice (WT), both on mRNA (2.24fold) and protein level (2.3fold). Egr1 stained 
positive in EC and vSMCs of collaterals as well as in nerves. In LDI measurements conducted over the 
period of 21 days evidenced a delayed perfusion recovery after femoral artery ligation in Egr1-/- mice 
compared to WT mice (day7: 0.46±0.05 in Egr1-/- vs. WT (0.73±0.04), day 14: 0.65±0.02 in Egr1-/- vs. 
0.88±0.04 in WT and day 21: 0.79 ±0.03 in Egr1-/- vs. 0.96±0.02 in WT). Under baseline conditions, 
Egr1-/- showed increased levels of monocytes (521.89±52.9 cells/µl vs. 326.56±21.6 cells/µl in WT) 
and granulocytes (811.79±79.96 cells/µl vs. WT 559.88±34.57 cells/µl) in the circulation but reduced 
levels in adductor muscles (18.14±2.73 cells/µl vs. 51.22±4.38 cells/µl in WT) as evidenced by FACS 
analyses. After femoral artery ligation, more macrophages were detected in the perivascular space of 
collateral arteries in Egr1-/- (8.10±0.99 per vessel) vs. WT (6.12±0.45 per vessel) mice. The mRNA of 
leukocyte recruitment mediators monocyte chemoattractant protein 1 (MCP-1), intercellular adhesion 
molecule 1 (ICAM-1) and urokinase plasminogen activator (uPA) were found upregulated in both 
groups. Whereas other Egr family members (Egr2-4) did not show an upregulation in WT collateral 
arteries, they were found significantly upregulated in Egr1-/- mice suggesting a mechanism of counter-
balancing Egr1 deficiency. A closer look at cell cycle regulators revealed that cyclin E and cdc20 were 
found upregulated in WT as well as in Egr1-/- mice. However, cyclin D1 was hardly detectable under 
Egr1 deficiency conferring Egr1 an unique role for cyclin D1 transcription. vSMC phenotype switch is 
a critical step towards vSMC proliferation and therefore arteriogenesis. In this context, the downregu-
lation of alpha smooth muscle actin (αSM-actin) and of the transcriptional repressor, splicing factor-1 
(SF-1) has been shown to be critical in vitro. During arteriogenesis, SF-1 has been found downregulat-
ed in collaterals of WT mice but was 1.64fold upregulated in Egr1-/-. Similar was true for αSM-actin. 
Whereas in WT mice αSM-actin is downregulated at 12h after ligation Egr1 deficient mice evidenced 
an upregulation of αSM-actin. The strong upregulation of the nonselective proliferation marker ki67 
in WT mice was not detectable under Egr1 deficiency evidencing furthermore a delay in vascular cell 
proliferation. Conclusion: Compensation for deficiency of Egr1 function in leukocyte recruitment can 
be mediated by other transcription factors; however, Egr1 is indispensable for effective vascular cell 
cycle progression and phenotype switch in arteriogenesis. 
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VIII. ZUSAMMENFASSUNG 
 
Chronische Ischämie von Herz und peripherer Muskulatur stellen für ein epidemiologisch bedeutendes 
Patientenkollektiv (Diabetiker, Hypertonie- und Arteriosklerosepatienten) oft eine therapeutisch aus-
weglose Situation dar. Eine Therapieoption für multimorbide Patienten, bei denen eine Bypassoperati-
on des Herzens nötig, aber nicht durchführbar ist, wären natürliche Bypässe, d.h. das Wachstum von 
präexistenten Kollateralgefäßen (Arteriogenese), die in der Lage sind eine entstandene Stenose funkti-
onell zu kompensieren. Entscheidende Schritte dieses Prozesses sind u.a. die Rekrutierung von Leuko-
zyten, insbesondere Monozyten in den perivaskulären Raum sowie die Proliferation von Endothel- 
und glatten Gefäßmuskelzellen der wachsenden Kollateralen. Da durch zahlreiche in vitro-Studien 
bekannt ist, dass der Transkriptionsfaktor „early growth response 1“ (Egr1) unter anderem für eben 
diese Prozesse eine Rolle spielt, war das Ziel dieser Arbeit, die Funktion von Egr1 im Prozess der 
Arteriogenese zu identifizieren und zu charakerterisieren. Zu diesem Zweck wurde das murine Model 
der peripheren Arteriogenese herangezogen, bei dem Arteriogenese durch Ligatur der Femoralarterie 
induziert wird. Egr1 war in den wachsenden Kollateralarterien sowohl auf RNA- (2.24fach) als auch 
auf Proteinebene (2.3fach) differentiell exprimiert und konnte immunhistologisch in Endothel- und 
glatten Gefäßmuskelzellen wachsender Kollateralerterien sowie in den perivaskulär liegenden Nerven 
lokalisiert werden. Laser Doppler Analysen von Egr1 defizienten (Egr1-/-) im Vergleich zu Wildtyp 
(WT)-Tieren zeigten eine verlangsamte Arteriogenese über den Zeitraum von 21 Tagen (Tag 7: 
0.46±0.05 in Egr1-/- vs. WT (0.73±0.04), Tag 14: 0.65±0.02 in Egr1-/- vs. WT (0.88±0.04) und an Tag 
21: 0.79 ±0.03 in Egr1-/- vs. WT (0.96±0.02)). Mittels FACS konnte gezeigt werden, dass Egr1-/- Mäu-
se unter Ruhebedingungen eine vermehrte Anzahl von Monozyten (521.89±52.9 Zellen/µl vs. WT 
(326.56±21.6 Zellen/µl)) und Granulozyten (811.79±79.96 Zellen/µl vs. WT 559.88±34.57 Zellen/µl) 
im Blut haben, aber eine reduzierte Anzahl an Makrophagen im Adduktorgewebe (18.14±2.73 
Zellen/µl vs. 51.22±4.38 WT Zellen/µl) zeigen. Nach Ligatur jedoch, konnte eine größere Anzahl 
Makrophagen um die Kollateralgefäße von Egr1-/- Mäusen (8.10±0.99 pro Gefäß) im Vergleich zu WT 
(6.12±0.45 pro Gefäß) detektiert werden, ein Hinweis auf eine Beeinträchtigung der Leukozytenrekru-
tierung unter Ruhebedingungen und eine Überkompensation mit verstärkter Anhäufung nach Setzens 
eines Stimulus. Bekannte Mediatoren der Monozytenrekrutierung „monocyte chemoattractant protein 
1“ (MCP-1), „intercellular adhesion molecule 1“ (ICAM-1) und „urokinase plasminogen activator“ 
(uPa), die in diesem Modell differentiell exprimiert sind, werden in der Literatur immer wieder mit 
Egr1 als potentielle „downstream“ Gene in Zusammenhang gebracht, zum Einen aufgrund ihrer Ex-
pressionsmuster (bei MCP-1 und ICAM-1), zum Anderen aufgrund ihrer strukturellen Promotercha-
rakteristika (bei uPa). Aber auch in Egr1 defizienten Tieren waren diese Mediatoren hochreguliert. 
Um der Frage nachzugehen, inwieweit Egr1 Funktionen von anderen Transkriptionsfaktoren über-
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nommen werden können, wurde mittels qRT-PCR die Expression anderer Egr-Familienmitglieder 
überprüft. Es zeigte sich, dass in WT Tieren die Egr Transkriptionsfaktoren Egr2-4 nicht hochreguliert 
waren, jedoch in Egr1 defizienten Tieren eine starke Hochregulation aller drei Faktoren, was für eine 
Teilkompensation durch Egr2-4 spricht. Neben der Monozytenrekrutierung ist die Proliferation von 
Endothel- und glatten Gefäßmuskelzellen ein zentraler Mechanismus der Arteriogenese. Egr1 kontrol-
liert die Zellproliferation über Expressionskontrolle der Zellzyklusregulatoren cyclin D1, E und cdc20 
in vitro. Cyclin E und cdc20 waren in WT und Egr1-/- Mäusen exprimiert. Allerdings war cyclin D1 in 
Kollateralgefäßen Egr1 defizienter Mäuse unterhalb der Nachweisgrenze. Grundvorraussetzung für die 
Proliferation glatter Gefäßmuskelzellen ist die Phänotypveränderung, der so genannte „phenotype 
switch“, vom kontraktilen zum synthetischen Typ. In diesem Zusammenhang ist bekannt, dass das 
zytoskelettäre Protein „alpha smooth muscle actin“ (αSM-actin) und der Transkriptionsrepressor 
„splicing factor-1“ (SF-1) charakteristischerweise herunterreguliert werden. In dieser Arbeit konnte 
gezeigt werden, dass dies auch in den wachsenden Kollateralen von WT Tieren der Fall ist. Jedoch 
zeigte sich in Egr1-/- Mäusen, dass SF-1 hochreguliert (1.64fach) und αSM-actin 12h nach Ligatur 
nicht mehr differentiell exprimiert war. In diesem Kontext konnte gezeigt werden, dass der Proliferati-
onsmarker ki67, der in WT deutlich hochreguliert ist, in Egr1 defizienten Tieren nicht mehr differenti-
ell exprimiert wird.  
Dies zeigt, dass die Egr1 Funktion im Bezug auf die Leukozytenrekrutierung durchaus durch andere 
Transkriptionsfaktoren und andere Mitglieder der Egr-Familie kompensiert werden kann, jedoch ist 
Egr1 entscheidend an der Transkription von cyclin D1 im Gefäß beteiligt und kontrolliert entschei-
dend die Regulation des „phenotype switch“. Aufgrund dieser Ergebnisse ist Egr1 unentbehrlich für 
eine funktionierende Zellproliferation und damit für die Arteriogenese. 
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X.  LIST OF ABBREVIATIONS 
 
 
A./a. arteria 
ADP adenosine diphosphate 
AMP adenosine monophosphate 
AMV-RT  avian myeloblastosis virus re-
verse transcriptase 
Ang-1  Angiopoietin-1  
AP1  APETALA1/activating protein 
1 
APE1  apurinic/apyrimidinic endonu-
clease 1 
ATP adenosine triphosphate 
αSM-actin  alpha-smooth muscle actin  
BCA bicinchoninic acid 
bp base pairs 
BSA  bovine serum albumine 
cAMP  cyclic adenosine monophos-
phate 
carp   cardiac ankyrin repeat protein  
CCD charge-coupled device 
CCL2   CC-chemokine ligand 2 
CCR-2  CC-chemokine receptor 2 
CD cluster of differentiation 
Cdc20  cell division cycle 20 
CDK cyclin dependent kinase 
CFIp   pressure- derived collateral 
flow index  
CP crossing point for targets 
CpR  crossing point for reference 
gene 
CpT crossing point for targets 
CREB  CRE binding protein  
CREs  cyclic adenosine monophos-
phate (cAMP) response ele-
ments  
CVDs  cardiovascular diseases 
CWS  circumferential wall stress  
DAB 3,3′-diaminobencidine 
DBD  DNA binding domain 
ddH20 double distilled water 
DNA desoxribonucleic acid 
dNTP  desoxyribonukleoside triphos-
phate 
DTT dithiothreitol 
E2F elongation factor 2 
EBS  early growth response binding 
sequence 
EC  endothelial cell  
ECG electrocardiography 
ECM extracellular matrix 
ECP external counter pulsation  
EDTA ethylenediaminetetraacetate 
Egr1  early growth response-1 
 gene symbol in mouse 
EGR1  early growth response-1 gene 
and protein symbol in humans, 
protein symbol in mouse 
Egr1-/-  early growth response-1 defi-
cient 
EGTA ethyleneglycoltetraacetate 
ELISA enzyme-linked immunosorbent 
assay 
Elk-1 Ets like gene 1 
eNOS endothelial nitric oxide syn-
thase 
EPCs   endothelial precursor cells 
ERK1/2  extracellular signal- regulated 
kinase 1/2 
Ets E-twenty six transcription fac-
tor 
FACS fluorescence activated cell 
FDA United States Food and Drug 
Association 
FGF  fibroblast growth factor 
FITC fluorescein isothiocyanate 
Flk1  fetal liver kinase 1 
Flt1  fms related tyrosine kinase1 
(VEGF receptor) 
FNA  flumazenile, naloxone, 
atipamezole 
FSS  fluid shear stress 
G-actin   globular actin 
G-protein guanine nucleotide-binding 
protein 
GAPDH glyceraldehyde 3-phosphate 
dehydrogenase 
GF  growth factors 
GMCSF  granulocyte macrophage colony 
stimulating factor 
GnRH  gonadotropin-releasing hor-
mone  
GTPase   small guanosine triphosphatase 
h hour(s) 
HASMC  human aortic smooth muscle 
cells 
HIF-1  inducible transcription factor 1 
i.p. intraperitoneal 
ICAM-1  intercellular adhesion molecule 
1 
ID inner diameter 
IF immunofluorescence 
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IHC immunohistochemistry 
IL  interleukin 
KCL potassium chloride 
kDa kilodalton 
LAD  left anterior descending 
LDI  laser Doppler imaging 
LFA-1 lymphocyte function-associated 
antigen 1 
LH   luteinizing hormone 
LIMK-1 LIM-kinase-1  
LPS lipopolysaccharides 
mAb monoclonal antibody 
m. musculus 
Mac-1 macrophage-1 antigen  
Mac-3 macrophage-3 antigen 
MAPKK/MEK   mitogen-activated protein ki-
nase kinase 
MCP-1 monocyte chemoattractant pro-
tein 1 
MCSF  macrophage colony-stimulating 
factor 
MEK mitogen-activated protein kina-
se kinase 
min minute(s) 
MIPs   macrophage inflammatory pro-
teins 
MKL myocardin-like protein  
ml mililiter 
mm millimeter 
mM millimolar 
MMF midazolam, medetomidin, fen-
tanyl (anesthesia) 
MMPs  matrix metalloproteinases 
mRNA messenger ribonucleic acid 
MRTF  myocardin-related transcription 
factor 
NAB   NGFI-A binding protein 
NaCl sodium chloride 
NaF sodium fluoride 
NFDM non-fat dry milk 
NFκB  nuclear factor kappa-light-
chain-enhancer of activated B 
cells 
NGF   neuronal growth factor  
NGFI-A   nerve growth factor inducible A  
NLS nuclear localization sequence  
NO  nitric oxide  
occ occluded side 
OD optical density 
P/T PBS/Triton buffer 
PAD peripheral arterial disease 
PBS  phosphate buffered saline 
PCI percutaneous coronary inter-
vention 
PCNA proliferating cell nuclear anti-
gen  
PDGF  platelet-derived GF  
PE phycoerythrin 
PECAM-1 platelet endothelial cell adhe-
sion molecule 1 
PMSF phenylmethanesulfonyl fluoride 
qRT-PCR quantitative real-time polymer-
ase chain reaction 
RANTES  regulated upon activation, nor-
mal T-cell expressed, and se-
creted 
Rb   retinoblastoma protein  
RF  risk factor 
Rho  Ras homologue 
ROCK   Rho-associated coiled-coil con-
taining protein kinase 
ROI region of interest 
ROS reactive oxygen species 
RPEL RPxxxEL-containing motif 
s.c. subcutaneous 
Sap 1/2 SRF accessory protein 1/2 
SDS-PAGE   sodium dodecyl sulfate-
polyacrylamide gel electropho-
resis 
sec second(s) 
SF-1  splicing factor-1 
sham sham operated side 
siRNA   small interfering RNA 
 sorting 
Sp1 gene-specific activator protein 
1 
SRE  serum response element 
SRF   serum response factor  
STEMI  ST-segment elevation myocar-
dial infarction  
TAE  Tris base, acetic acid EDTA 
TBS  Tris buffered saline 
TCF  ternary complex factor  
TCF  ternary complex factors 
TF  transcription factor 
TGF-ß1  transforming growth factor beta 
1  
Tie-2 angiopoietin receptor 2 
tPA  tissue plasminogen activator  
Tris  tris (hydroxymethyl) amino-
methane 
uPA   urokinase plasminogen activa-
tor  
uPAR urokinase plasminogen activa-
tor receptor 
µg   microgram  
µl   microliter  
VCAM-1 vascular cell adhesion mocule1 
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VEGF   vascular endothelial growth factor  
vSMC   vascular smooth muscle cell 
WB western blot 
WHO World Health Organization 
WT wild type 
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